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A B S T R A C T
Background
High grade glioma (HGG) is an aggressive form of brain cancer. Treatment of HGG usually entails biopsy, or resection if safe, followed
by radiotherapy. Temozolomide is a novel oral chemotherapy drug that penetrates into the brain and purportedly has a low incidence
of adverse events.
Objectives
To assess whether temozolomide has any advantage for treating HGG in either primary or recurrent disease settings.
Search methods
The following databases were searched: CENTRAL (Issue 10, 2012), MEDLINE, EMBASE, Science Citation Index, Physician Data
Query and the Meta-Register of Controlled Trials in October, 2012. Reference lists of identified studies were searched. The Journal
of Neuro-Oncology and Neuro-oncology were handsearched from 1999 to 2012 including conference abstracts. We contacted neuro-
oncologists regarding ongoing and unpublished trials.
Selection criteria
Randomised controlled trials (RCTs) where the interventions were the use of temozolomide during primary therapy or for recurrent
disease. Comparisons included no chemotherapy, non-temozolomide chemotherapy or different dosing schedules of temozolomide.
Patients included those of all ages with histologically proven HGG.
Data collection and analysis
Two review authors undertook the quality assessment and data extraction. Outcome measures included: overall survival (OS); progres-
sion-free survival (PFS); quality of life (QoL); and adverse events.
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Main results
For primary therapy three RCTs were identified, enrolling a total of 745 patients, that investigated temozolomide in combination with
radiotherapy versus radiotherapy alone for glioblastoma multiforme (GBM). Temozolomide increased OS (hazard ratio (HR) 0.60,
95% confidence interval (CI) 0.46 to 0.79, P value 0.0003) and increased PFS (HR 0.63, 95% CI 0.43 to 0.92, P value 0.02), when
compared with radiotherapy alone, although these benefits only appear to emerge when therapy is given in both concomitant and
adjuvant phases of treatment. A single RCT found that temozolomide did not have a statistically significant effect on QoL. Risk of
haematological complications, fatigue and infections were increased with temozolomide.
In recurrent HGG, two RCTs enrolling 672 patients in total found that temozolomide did not increase OS compared to standard
chemotherapy (HR 0.9, 95% CI 0.76 to 1.06, P value 0.2) but it did increase PFS in a subgroup analysis of grade IV GBM tumours
(HR 0.68, 95% CI 0.51 to 0.90, P value 0.008). Adverse events were similar between arms.
In the elderly, 2 RCTs of 664 patients found OS and PFS was similar with temozolomide alone versus radiotherapy alone. QoL did
not appear to differ between arms in a single trial but certain adverse events were significantly more common with temozolomide.
Authors’ conclusions
Temozolomide when given in both concomitant and adjuvant phases is an effective primary therapy in GBM compared to radiotherapy
alone. It prolongs survival and delays progression without impacting onQoL but it does increase early adverse events. In recurrent GBM,
temozolomide compared with standard chemotherapy improves time-to-progression (TTP) and may have benefits on QoL without
increasing adverse events but it does not improve overall. In the elderly, temozolomide alone appears comparable to radiotherapy in
terms of OS and PFS but with a higher instance of adverse events.
P L A I N L A N G U A G E S U M M A R Y
Temozolomide for brain cancer
High grade glioma (HGG) is a rapidly progressive form of brain cancer with a poor survival rate even after standard treatment with
surgery and radiotherapy. Temozolomide is an oral anti-cancer drug.
Three randomised controlled trials (RCTs) enrolling patients with newly diagnosed glioblastoma multiforme (GBM - a form of HGG)
have studied chemotherapy with temozolomide during and after radiotherapy. This was compared with radiotherapy only.
Those who received temozolomide had an improved survival and delayed progression of the disease. The short-term adverse events
associated with temozolomide are low but can be severe, while the long-term effects are unknown. No RCTs investigated the use of
temozolomide in HGGs other than GBM. In recurrent GBM, temozolomide delayed progression but did not improve overall survival.
In the elderly population (age over 60 years), temozolomide alone appears to be a suitable alternative to radiotherapy alone for primary
therapy of GBM. Either treatment has similar overall survival, progression-free survival and quality of life, but there are possibly more
adverse events with temozolomide.
All these trials enrolled highly selected patients with good prognostic features that are not entirely representative of all patients with
HGG limiting the general applicability of these results.
B A C K G R O U N D
Description of the condition
Gliomas are tumours of the brain and spinal cord, so called be-
cause they develop from the glial cells which form structures that
surround and support neurons. Gliomas are graded by the World
Health Organization classification on a scale of I to IV based on
the histological appearance of the tumour (Louis 2007, Kleihues
1993). Grades III and IV are classified as high grade gliomas
(HGG) and have in common an aggressive and infiltrating na-
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ture. The majority of HGG are glioblastoma multiforme (GBM),
anaplastic astrocytoma (AA) and anaplastic oligodendrocytoma
(AO). The incidence of HGG is less than 8 per 100,000 per year,
resulting in around 4800 new cases in the UK each year (Counsell
1996). Overall, HGGmake up about one per cent of all new can-
cers diagnosed each year (SHS 2006).
Description of the intervention
In general HGGs have a poor prognosis, are rapidly progressive,
and resistant to therapy. Their infiltrating nature means they can-
not be completely excised and themajority will recur locally (Giese
2004). Management is based on symptomatic relief, optimising
quality of life, and increasing survival. Securing a histological di-
agnosis entails either biopsy or resection. Currently, there is only
a single small RCT of biopsy versus resection that is of too poor
methodological quality to reach definitive conclusions, although
non-randomised studies (NRS) have suggested that resection is
desirable when it can be achieved safely (Hart 2011a). Radiother-
apy forms the mainstay of treatment, resulting in an increase in
median survival from three to four months to around nine to ten
months (Walker 1978). Medical therapy primarily involves glu-
cocorticosteroids which often produce a marked improvement in
neurological symptoms and survival by themselves (Kaal 2004).
Chemotherapy has been used for primary therapy as either sin-
gle agent or multi-agent regimens. Results have generally been
conflicting and significant systemic toxicity is possible (Rampling
2005). A meta-analysis of chemotherapy in HGG has demon-
strated an improvement in survival with PCV (procarbazine, lo-
mustine and vincristine) chemotherapy (HR 0.85, CI 0.78 to 0.92
P < 0.0001) with an overall improvement of two months in me-
dian survival to around 12 months (GMT Group 2002). It is
not clear whether the gain in survival reflects a useful period of
good quality of life (QoL). In grade III tumours, two RCTs did
not demonstrate an increase in overall survival (OS) with systemic
chemotherapy (Cairncross 2006; van den Bent 2006).
How the intervention might work
Temozolomide is a chemotherapy drug that methylates DNA in
a way which prevents tumour cell proliferation. It is easily admin-
istered in an out-patient setting as an oral agent. Penetration into
brain tumours and through the blood brain barrier is good which
should potentially maximise effectiveness and limit systemic tox-
icity.
Why it is important to do this review
Early case series have suggested temozolomide to be a safe therapy,
with haematological toxicity of 5 to 10%, and is associated with a
good median survival of around 16months (Lanzetta 2003; Stupp
2002). These survival figures compared favourably with expected
prognosis in GBM, while toxicity was lower than with traditional
PCVbased chemotherapy regimens. Adjuvant temozolomide after
GBM resection is rapidly becoming the standard of care in the
primary disease setting, but this practice has largely been based on
a single high profile RCT, with no systematic review and meta-
analysis in the field to fully assess the evidence basis for this trend
in clinical practice.
O B J E C T I V E S
The aimof this review is to assess the effectiveness of temozolomide
in HGG.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs).
Types of participants
• Primary therapy i.e. in newly diagnosed disease not
previously treated. Participants were patients of any age with a
histologically confirmed HGG. They may have undergone any
form of surgery to reach a histological diagnosis (biopsy or
resection).
• Recurrent disease i.e. previously treated disease. Participants
were patients of all ages with a previous histologically confirmed
HGG and presumed recurrent disease. Recurrent disease must
have been confirmed by both clinical and radiological criteria
(Wen 2010). Prior treatment with temozolomide was not a
contra-indication to inclusion.
• Specific HGG include glioblastoma multiforme (GBM),
anaplastic astrocytoma (AA), anaplastic oligodendrocytoma
(AO) and mixed anaplastic oligoastrocytoma (AOA).
• Patients should be stratified for age, performance status and
histology (the main prognostic factors) in order to provide
comparable treatment arms. Performance status was recorded
using the Karnofsky Performance Score (KPS) (Karnofsky 1948)
or World Health Organization (WHO) score.
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Types of interventions
• Treatment arms: the intervention under investigation was
the use of oral temozolomide.
• Control arms: different dosing regimens of temozolomide
were eligible for inclusion but were subject to subgroup analysis.
Inclusion of systemic chemotherapy in the control arm was not
stipulated as this is not necessarily part of standard practice in all
countries, however, in light of good evidence for the effectiveness
of PCV chemotherapy in primary disease (GMT Group 2002), a
subgroup analysis was performed. The use of chemotherapeutic
wafers was also eligible for inclusion as part of the comparison
arm but subjected to subgroup analysis.
• Differerent doses of radiotherapy were eligible:
e.g.,standard dose (e.g. 60 Gy in 30 fractions of 2 Gy over 6
weeks), limited dose, or part of the intervention.
• Post-operative management: this includes medical
management of seizures, symptom control, and
glucocorticosteroids for brain oedema, symptoms of raised intra-
cranial pressure or focal deficits. Similar care should have been
given to both arms, ideally conforming to established practice
(Grant 2004; Rampling 2005)
Types of outcome measures
Ideally all outcome measures should have been assessed by at least
two independent assessors at frequent intervals.
Primary outcomes
• Overall survival (OS): from time of randomisation to time
of death.
Secondary outcomes
• Time-to-progression (TTP)/progression-free survival (PFS):
open and thorough criteria should be used to define recurrence
according to clinical symptoms, imaging or increasing steroid
therapy (Wen 2010).
• Quality of life (QoL): a reliable and objective grading
measure should be used, for example the EORTC QLQC30/
BN-20 and FACT-BrS (Mauer 2008).
• Adverse events: nature (as defined using MedDRA (Medical
Dictionary for Regulatory Authorities) criteria), timing and
grade (only severe grade 3 to 4 included). Specific relevant
examples include: haematological, fatigue, thromboembolic and
infection. Further procedures required for complications should
be noted. Both the total number of complications and
complications per patient should be stated.
Search methods for identification of studies
Electronic searches
The full search strategies for both the original review and the
update are described in Appendix 1; Appendix 2; Appendix 3;
Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9. Foreign language journals were eligible for inclusion.
The dates for the updated searches were:
MEDLINE: 2007 to October week 2 2012
EMBASE: 2007 to 2012 week 42
CENTRAL Issue 10 2012
Searching other resources
The references of all identified studies were searched to identify
more RCTs.
Handsearch
A handsearch of the Journal of Neuro-Oncology from 1991 to De-
cember 2012 was undertaken in order to identify trials that may
not have been present in the electronic databases. This included
searching all conference abstracts published in the journal.
Personal communication
We contacted the manufacturer of the temozolomide brand
Temodar/Temodal® (Merck&Co formerly Schering-Plough) for
information regarding any further RCT(s) using their product.
We contacted the following researchers by e-mail for information
on any current or pending RCTs for the 2013 update: Prof Susan
Short; Prof Dr Roger Stupp; Prof Dr (med) Michael Weller; Prof
Dr Wolfgang Wick.
Data collection and analysis
Selection of studies
Identification of studies was made in two stages (Figure 1). In this
update two review authors (MGH & RG) independently exam-
ined the abstracts returned by the search. Those studies that clearly
did not meet the inclusion criteria were excluded and copies of
the full text of potentially relevant references were obtained. The
same two authors independently examined the full texts of the se-
lected references for inclusion or exclusion criteria. At all times any
disagreements were resolved through discussion. If sufficient data
were not available for assessment then we contacted the relevant
authors of the trials.
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Figure 1. Study flow diagram: search strategy update 2007 - 2012
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Data extraction and management
For the included studies, a single review author (MGH) indepen-
dently abstracted data on characteristics of patients and interven-
tions, study quality, endpoints and deviations from protocol us-
ing a pre-specified form designed to complete the information re-
quired for the table of Characteristics of included studies, Table
1 and Table 2. Differences were reconciled by discussion or by
consultation with a third review author.
Data integration to RevMan 5.1 was performed by a single review
author (MGH).
Assessment of risk of bias in included studies
Trials deemed relevantwere critically appraised according to check-
list (Fowkes 1991) and the criteria reported in the NHS CRD
Report No. 4. We constructed tables to summarise internal and
external validity (Juni 2001). Risk of bias was ascertained as de-
scribed in the Cochrane Handbook of Systematic Reviews of Inter-
ventions (Higgins 2009). Two review authors (MGH & RG) per-
formed the critical appraisal. Any disputes were resolved through
discussion.
Measures of treatment effect
• For time to event data (OS and TTP/PFS), we abstracted
the hazard ratio (HR) and its variance from trial reports; if these
were not presented, we attempted to abstract the data required to
estimate them (Parmar 1998).
• For dichotomous outcomes (e.g. adverse events), we
abstracted the number of patients in each treatment arm who
experienced the outcome of interest, in order to estimate a odds
ratio (OR). For continuous outcomes (e.g. QoL) the final value
and standard deviation of the outcome of interest in each
treatment arm at the end of follow-up was abstracted for each
study.
• For continuous outcomes (e.g. QoL), the final value and
standard deviation of the outcome of interest in each treatment
arm at the end of the follow-up was abstracted for each study.
• For dichotomous and continuous data, we abstracted the
number of patients assessed at endpoint.
Unit of analysis issues
For time to event data (OS and TTP/PFS), if the HR and its
variance was not presented, we attempted to abstract the data
required to estimate them (Parmar 1998).
Dealing with missing data
Loss to follow-up: the number of participants lost to follow-up in
each intervention arms whose outcomes were not reported at the
end of the study was recorded; we also noted if loss to follow-up
was not reported.
In the case of missing data required for the review outcomes, we
contacted the study authors.
Assessment of heterogeneity
Visual inspection of forest plots in combination with the Chi2 test
were used to gauge whether trials were of sufficient homogeneity
to be combined in a meta-analysis.
Assessment of reporting biases
Where possible, all data abstracted were those relevant to an in-
tention-to-treat analysis. A funnel plot of treatment effect versus
precision with the data from all studies was performed in order to
investigate the likelihood of publication bias.
Data synthesis
We pooled the results of trials of primary therapy and recurrent
disease into separate meta-analyses.
• For time to event data, HR and its variance were pooled
using the generic inverse variance facility of RevMan 5.1.
• For continuous outcomes, we pooled the mean differences
between the treatment arms at the end of follow-up using the
mean difference (MD) method if all trials have measured the
outcome on the same scale, or using the standardised mean
difference (SMD) method otherwise.
• For dichotomous outcomes, we calculated the OR for each
study and then all studies were pooled.
We performed both fixed-effect and random-effects models for all
meta-analyses (Der Simonian 1986).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses included: various temozolomide dosing reg-
imens (e.g. standard ’Stupp regime’, ’dose dense’, ’metro-
nomic’, ’prolonged course’), systemic chemotherapy, chemother-
apy wafers, studies with a minimum age criteria, and different ra-
diotherapy dosing schedules.
Sensitivity analysis
Assessment were performed without trials at significant risk of
bias or if the methodology was significantly different from other
studies to determine the effects on the overall conclusions.
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R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
For the update in 2013, the total additional number of studies
identified by the literature searches since the original 2008 review
were:
• MEDLINE: 1026
• EMBASE: 2006
• CENTRAL: 261
From these, a total of 61 abstracts were reviewed and 28 articles
were chosen for retrieval because they either met the inclusion
criteria or insufficient data were available. Subsequently, 10 new
articles, 7 included and 3 excluded, were added to the current
version of the review and 18 were excluded.
Included studies
Primary therapy
In total eight RCTs (presented in eleven articles) met the inclusion
criteria (Description of studies).
• Temozolomide and radiotherapy versus radiotherapy
alone
EORTC/NCIC 26981-22981
This RCT (EORTC 26982-22981/NCIC CE3) involved 85 cen-
tres in 15 Europe and Canada enrolling 573 patients between
2000 to 2002. The primary hypothesis was to assess concomitant
and adjuvant temozolomidewith radiotherapy versus radiotherapy
alone in primary therapy for histologically confirmed GBM only
in patients who had undergone biopsy or resection but excluding
patients over 70 years old. Inclusion criteria were: age between 18
to 70, stable steroid requirements, adequate baseline blood tests,
and aWHO performance score of two or less (Table 3). Exclusion
criteria were not specified. Histology was centrally verified. Stan-
dard radiotherapy schedules of 60Gy for six weeks was given to
both arms. The treatment arm comprised of temozolomide 75mg/
m2 daily during radiotherapy then up to six adjuvant cycles of 150
to 200mg/m2 for one to five out of every 28 days for a total of six
further cycles. No routine chemotherapy was given to the control
arm. Subsequent management was given according to need with
no pre-specified protocol mentioned. The primary end point was
OS; secondary endpoints included PFS, safety and QoL (reported
separately). Definitions were given for progression (radiological or
increasing steroids), extent of surgery (surgeon’s opinion) and ad-
verse events (National Cancer Institute Cancer Treatment Criteria
(NCICTC)). Follow-up was at baseline, 28 days after completing
radiotherapy, and thereafter, at three-monthly intervals.
A follow-up report had increased median follow-up and a further
multivariate analysis on putative prognostic factors. Data from
this report were chosen for inclusion in the meta-analysis over the
earlier reported findings due to the improved follow-up.
Quality of life data (QoL) was reported in a separate article. Ad-
ditional outcome measures included the EORTC QLQ-C30 and
QLQ-BCM20 as combined outcome measures which were then
converted to a score of 0 to 100 (with a higher score translating
to a higher level of functioning or symptoms). The difference be-
tween groups and from baseline was recorded for seven groups
(overall, fatigue, social function, emotional function, future un-
certainty, insomnia and communication deficit), based on previ-
ous experience with temozolomide, to reduce multiple testing er-
rors. Differences of at least 10 points were classified as clinically
meaningful. Compliance with questionnaires was also recorded.
Follow-up was: prior to treatment; week four of radiotherapy; four
weeks after completing radiotherapy; at the end of the third and six
month of adjuvant temozolomide; and three-monthly afterwards
until disease progression. Standard EORTC procedures were used
for completing, handling and analysing the data from the forms.
Athanassiou 2005
Thiswas a randomised phase II study set in a single centre inGreece
enrolling 130 patients from 2000 to 2002. The primary hypothe-
sis was to test the concomitant and adjuvant temozolomide (using
a novel dose intensification schedule) with radiotherapy versus ra-
diotherapy alone in primary therapy for newly diagnosed patients
with GBM. Patients were randomised to either radiotherapy and
temozolomide (concomitant and adjuvant) or radiotherapy alone.
It used a dose intensification schedule of temozolomide in the ad-
juvant phase involving 150mg/m2 temozolomide on days 1 to 5
and days 15 to 19. In the concomitant phase temozolomide was
administered using a standard 75mg/m2 daily dose throughout.
Radiotherapy was administered to both arms in a dose of 60 Gy
over 6 weeks. Inclusion criteria were: GBM on histology, KPS of
60 or more (Table 4), and age over 18 (but with no upper age
limit specified). Exclusion criteria were: poor medical condition.
Primary outcome measures were OS and TTP; secondary out-
come measures included toxicity. Follow-up was weekly clinical
assessment during radiotherapy, weekly blood tests during ther-
apy, and MRI scans every two to three months. Definitions were
specified for progression (multifactorial including imaging, neu-
rological and clinical factors) and adverse events (NCICTC).
Kocher 2008
This was a multi-institutional study on primary treatment for
GBM based on a German neuro-oncology network recruiting 65
patients between 2002 and 2004. Recruitment was stopped short
of the power calculation target of 500 due to the publication of
results from a similar RCT (EORTC/NCIC 26981-22981). It fo-
cused on patients at primary therapy with a confirmed GBM with
complete tumour resection treatedwith concomitant radiotherapy
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and temozolomide (but not adjuvant temozolomide) compared
with radiotherapy only. Inclusion criteria were: age 18 to 70, uni-
focal GBM, macroscopic tumour resection (based on early CT
and MRI), PS 0 to 2 (Table 3), and stable labs. Exclusion criteria
were: recurrent disease, prior therapy, other major medical illness
or infection, previous malignancy, and pregnancy. Radiotherapy
involved 60 Gy in 2.0 Gy daily fractions 5 days per week. The
treatment arm was: temozolomide 75mg/m2 on days 1 to 28. The
control arms: radiotherapy alone (no further therapy). Follow-up
was based on clinical assessment, WHO assessment, and MRI at
least three-monthly.Outcomes were:OS, PFS, and adverse events.
Definitions were given for progression (multifactorial) and extent
of resection. Further outcome data were supplied by the authors.
• Temozolomide versus radiotherapy in the elderly
Nordic 2012
The was a randomised, controlled phase III study involving 28
predominantly European oncology centres enrolling 342 patients
between 2000 and 2009. It focused on patients over 60 years old
with a histologically confirmedWHO grade IV astrocytoma. The
primary hypothesis was to test if chemotherapy with temozolo-
mide was similar to or better than hypofractionated radiother-
apy (deemed the current standard of care for elderly patients) or
standard radiotherapy in terms of survival but with an improved
QoL and adverse events profile. Additional inclusion criteria were:
WHO performance score 0 to 2 (or 3 if a neurological deficit); ad-
equate haematological, renal and liver function; and were expected
by the doctor to tolerate all treatment options. After 2004 patients
deemed fit to receive combination treatment were excluded based
on the results of another trial (EORTC/NCIC 26981-22981). Ex-
clusion criteria were: another primary cancer;WHO performance
score 3 to 4; any disorder likely to interfere with study treatment;
previous therapy for a brain tumour; and previous radiotherapy
to the head that would prevent further irradiation. Patients were
randomised depending on the institution to either 1:1:1 in blocks
of 9 to temozolomide, hypofractionated radiotherapy, or standard
radiotherapy; or in blocks of 8 to either temozolomide or hypofrac-
tionated radiotherapy. Blinding was not used. Temozolomide was
administered orally in 200mg/m2 doses on days 1 to 5 of every 28
days for up to six cycles or until radiological progression, clinical
progression, or both, unacceptable adverse effects were seen, or
until a physician or patient chose to discontinue treatment. Hy-
pofractionated radiotherapy was administered in 6 fractions of 5.0
Gy for 3 days a week over 2 weeks of 34.0 Gy delivered in 10 frac-
tions of 3.4 Gy on 5 days a week over 2 weeks. Standard radiother-
apy was 60.0 Gy in 30 fractions of 2.0 Gy over 6 weeks. Outcome
measures were: EORTCQLQC-30 andBN-20. Assessments were
at 6 weeks, 3 months and 6 months. Adverse events were assessed
by the WHO grading system except nausea and vomiting which
were assessed by the NCIC version 2.0. Further therapy was at
the discretion of the treating physician. The power calculation was
that 480 patients with 160 per treatment group was need to detect
a 10% survival difference (i.e. 10 to 20% at 1 year) with a 90%
power at the 5% significance level. Spoonsors had no role in the
study design, data collection, data analysis, data interpretation, or
writing of the report.
NOA-08 2012
This is a randomised, phase III trial recruiting 412 patients from
23 university centres across Germany and one in Switzerland from
2005 to 2009.The primary hypothesis was to assess whether temo-
zolomide (dose-dense schedule) alone is inferior to radiotherapy
alone (i.e. a non-inferiority study) in the primary therapy of HGG
(either GBM or AA). A further aim was to investigate the role of
O6-methylguanine-DNA methyltransferase (MGMT) promotor
methylation. Inclusion criteria were: de-novo anaplastic astrocy-
toma or glioblastoma; age older than 65; and a Karnofsky perfor-
mance score (KPS) of 60 ormore. Exclusion criteria were: previous
chemotherapy or radiotherapy to the brain; inadequate bone-mar-
row reserve, liver function or renal function. Temozolomide was
administered according to a 1 week on, 1 week off schedule, with
100mg/m2 on days 1 to 7 with increases or decreases in 25mg/
m2 depending on blood-cell counts and general tolerability. Ra-
diotherapy was administered to the gross tumour volume plus a
2cm margin over 6 to 7 weeks in fractions of 1.8-2.0 Gy to a total
of 60 Gy. Tumour response or progression was defined according
to the Macdonald criteria. Methylation of the MGMT promotor
was assessed with two distinct methylation-specific PCR assays.
The primary endpoint was overall survival. Secondary endpoints
included event-free survival (EFS), best response, health-related
(HR) QoL, and safety. The sponsor had no role in the study de-
sign, data collection, data analysis, data interpretation or writing
of the report.
• Different Temozolomide dose schedules
Clarke 2009
This was a single institution study based in the USA recruiting 85
patients with newly diagnosed GBM at pathology between 2005
to 2007. The primary hypothesis was to test the efficacy of dose
dense versus metronomic temozolomide in the adjuvant phase of
treatment after both arms had received standard radiotherapy and
concomitant temozolomide. Inclusion criteria were: age 18 to 70
and KPS (Table 4) greater than or equal to 60. Exclusion criteria
were: other cancer, abnormal baseline blood tests, pregnancy, and
nursing. The treatment arm comprised of ’dose dense’ temozolo-
mide 150 mg m2 on days 1 to 7 and 15 to 21 of every 28 days cy-
cle. The control arm consisted of ’metronomic’ temozolomide at
50mg/m2 on days 1 to 28 of adjuvant therapy. Both arms received
standard radiotherapy (60 Gy in 30 doses over 6 weeks includ-
ing intensity modulated therapy) and concomitant temozolomide
75mg/m2 daily as well as 13-cis-retinoic acid after treatment was
completed. Outcome criteria were: MacDonald criteria & MRI
2/12. Definitions were specified for progression (MacDonald cri-
teria), pseudo-progression, and adverse events (NCI CTC). Data
for survival and PFS were estimated from the Kaplan-Meier plots.
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Recurrent disease
In total two RCTs presented in three articles were retrieved.
• Temozolomide versus nitrosourea based chemotherapy
Yung 2000a
This was a multicentre, multinational randomised phase II study
enrolling 225 patients between 1995 and 1997. The primary
hypothesis was to compare temozolomide with procarbazine
(deemed best standard therapy at recurrence) for recurrent GBM
previously confirmed on histology. Inclusion criteria were: age 18
or over, confirmed GBM or gliosarcoma, a KPS of 70 or more
(Table 4), a life expectancy of 12 weeks or more, and unequiv-
ocal evidence of tumour progression at first relapse on MRI or
enhanced CT after radiation therapy. Exclusion criteria were ab-
normal baseline blood tests, multiple previous chemotherapy reg-
imens and other systemic illnesses (detailed within article). The
treatment arm consisted of temozolomide150 to 200mg/m2 on
days 1 to 5 of 28 depending on previous exposure to temozolo-
mide. The control arm consisted of procarbazine 125 to 150mg/m
2 administered for 28 days out of every 56 depending on previous
exposure. No radiotherapy was administered to either arm at re-
currence (both had previously received radiotherapy as stipulated
in the inclusion criteria). Outcome measures were OS, PFS, QoL,
treatment response and adverse events. Definitions were given for
QoL (measured by EORTC QLQ-C30 and QLQ-BCM20), ob-
jective responsiveness and adverse events (NCICTC).
A separate article documented the QoL data. Please note that for
the original review in 2008 this study was excluded due to difficul-
ties in assessing the QoLpresented, but subsequently for the 2013
update there was greater experience in assessing the reliability of
this data and it was possible to included the study. Consequently,
the trialmethodology, intervention and follow-upwere identical to
that previously described. Additional outcome measures were the
EORTC-QLC30 and BCM20 questionnaires focusing on QoL.
Follow-up was prior to each cycle of chemotherapy. Scoring was
according to standard procedures with conversion to a range of
0 to 100 and higher scores indicating better functioning or more
symptoms. To reduce error due to repeat statistical testing seven
criteria were chosen pre-hoc for testing based on prior knowledge.
Changes were assessed at six months as well as prior to, and at the
time of, disease progression. The significance of changes was de-
termined by statistics, effect sizes, and the proportions of patients
with an improvement of ten points or more (the minimum con-
sidered clinically significant: smaller changes were disregarded).
BR12 2010
This is a multicentre RCT based in the UK recruiting 447 pa-
tients between 2003 to 2007. The primary hypothesis was to test
whether temozolomide (in either of twodifferent dosing regimens)
versus PCV chemotherapy in a variety of HGG (grades 3 and 4)
at recurrence after initial therapy. Inclusion criteria were an in-
terval of over two months since completing primary therapy, a
life expectancy of over one month, adequate baseline laboratory
function and general fitness to commence further therapy. Exclu-
sion criteria were pregnancy, oligodendroglial histology, a WHO
score of four (Table 3), and previous chemotherapy, radiosurgery
or brachytherapy. The treatment arm consisted of either temozolo-
mide 200mg/m2 for days 1 to 5 of 28 (TMZ-5) or temozolomide
100mg/m2 for days 1 to 21 of 28 (TMZ-21 or ’dose dense’). The
control arm consisted of standard PCV chemotherapy (at stan-
dard doses) every six weeks until progression or six cycles in total.
Outcomes were OS, PFS, and QoL. Definitions were given for
recurrence (multifactorial) and QoL.
Excluded studies
For the 2008 publication we excluded 339 references and retrieved
12 for detailed evaluation.Of these we excluded 7 for the following
reasons (see table of excluded studies):
• Two phase II studies of temozolomide for primary therapy
in GBM (Stupp 2002; Lanzetta 2003)
• Two phase II studies of temozolomide in therapy for
recurrence of GBM (Bower 1997; Yung 2000b)
• One phase II study of temozolomide for anaplastic
astrocytoma or oligoastrocytoma at first relapse (Yung 1999)
• One QoL review of an included RCT (Osoba 2000b)
• One single centre retrospective series of temozolomide for
both primary and recurrent therapy (Newlands 1996)
• One study that was excluded for the 2008 publication was
subsequently included in the 2012 update due to improvements
in data analysis (Osoba 2000a).
For the 2013 update we excluded an additional 18 studies.
• Nine abstracts of conference proceedings were excluded due
to a lack of complete presentation of the final results (Gilbert
2010; Kim 2010; Naboors 2009; Najak 2010; Malmstrom 2010;
Malmstrom 2010b; Renard 2010; Weller 2010; Wick 2010; )
• One RCT because of insufficient data presentation (Qian
2009).
• Three because they were a review, commentary or
presentation of an included RCT (Hamilton 2006; Lee 2008;
Linz 2009).
• Two meta-analysis of RCTs Spiegel 2007; Wang 2010.
• Two because the study question was based on the benefit of
an additional therapy with temozolomide as the control arm.
One study considered the benefit of erlotinib (a tyrosine kinase
inhibitor) versus temozolomide or carmustine in patients with
recurrent GBM (van den Bent 2009). Another compared
trabedersen (a TGF B2 antisense oligodeoxynucleotide) in one of
two doses delivered through an intra-tumoural convection
enhanced delivery system with best medical care (involving
either standard dose temozolomide or PCV) for recurrent/
refractory HGG (Bogdahn 2011).
• One RCT tested if initial upfront chemotherapy alone
(with either PCV or temozolomide) was as efficacious as initial
radiotherapy alone regarding time to treatment failure with a
randomisation schedule of 1:1:2.compared (Wick 2009).
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However, individual results for the temozolomide arm were not
reported prohibiting inclusion in the review.
Risk of bias in included studies
A full analysis of the internal validity of the included studies is
described in Table 1. The salient points are outlined below and in
Figure 2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Primary therapy
The differences in trial methodology, participants and interven-
tions were not of sufficient clinical significance to preclude meta-
analysis.The three RCTs of temozolomide and radiotherapy ver-
sus radiotherapy alone in HGG were suitable for meta-analy-
sis (Athanassiou 2005; EORTC/NCIC 26981-22981; Kocher
2008). Subgroup analysis was indicated for: concomitant and ad-
juvant temozolomide (Athanassiou 2005; EORTC/NCIC 26981-
22981) or versus concomitant but not adjuvant temozolomide
(Kocher 2008). Separate meta-analyses were required for different:
dosing schedules of temozolomide (Clarke 2009); and temozolo-
mide versus radiotherapy in the elderly (Nordic 2012; NOA-08
2012)
Therapy for recurrent disease
The differences in trial methodology, participants and interven-
tions were not of sufficient clinical significance to preclude meta-
analysis.
Allocation
Studies at low risk of allocation (selection) bias included BR12
2010; Clarke 2009; EORTC/NCIC 26981-22981. These all had
excellent methods of randomisation, appropriate use of strati-
fication, and clear power calculations that were achieved. Se-
lected studies did not clearly report their methods of randomi-
sation, if stratification was used, and on allocation concealment
(Athanassiou 2005; Yung 2000a). In certain instances the study
groups were not similar at baseline which could be indicative of
selection bias. For example in the trial by Yung 2000a there was
a greater time to relapse from initial diagnosis or radiotherapy for
the procarbazine arm. It is not clear however if this is a marker for
prognosis or different disease characteristics. In the trial by Kocher
2008 baseline characteristics appeared to suggest more males and
more patients with seizures were present in the radiotherapy alone
arm. A lack of statistical tests for baseline characteristics was ap-
parent in a single trial (EORTC/NCIC 26981-22981).
Blinding
The most serious concern relating to all the included trials related
to the lack of blinding or use of placebo, which raises concerns
of bias in outcome assessment and in post-treatment therapy. Un-
blinded studies are known to over-estimate treatment effects such
as disease progression (Juni 2001).
This may lead to bias in reporting all non-objective outcome mea-
sures (essentially everything apart from OS) including PFS, TTP,
QoL and adverse events. It is recognised that one of the reasons
given for not using a placebo (and therefore allowing blinding) is
obvious changes in blood parameters that can occur during che-
motherapy.
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Incomplete outcome data
All studies analysed there data on an intention-to-treat basis ex-
cept one (Athanassiou 2005): in this trial 20 out of 130 patients
were withdrawn from the analysis after randomisation. Two used
a modified intention-to-treat analysis only analysing those that
actually received treatment (NOA-08 2012; Nordic 2012). All
studies recording QoL data had as expected significant difficulties
with attrition bias (EORTC/NCIC 26981-22981; Osoba 2000b;
NOA-08 2012; Nordic 2012). Recognition of these limitations
and methodology to minimise these effects were commendable.
Selective reporting
In the trial by Yung 2000a measures used for analysing QoL were
ideal but methods of analysis less than optimal: changes were only
evaluated at six months or at disease progression limiting sensi-
tivity. The issue of blinding and recording of QoL outcomes is of
particular concern given the subjective nature of recording such
data. The intervals between recordings of data (three-monthly)
were long enough to introduce some lag time bias i.e. a lack of
sensitivity in detecting actual timing of events.
Other potential sources of bias
Quality of life data proved troublesome to integrate directly into
RevMan. Outcome data for QoL were included in a descriptive
manner because of this and because there were relatively few trials.
Alternative methods of presenting the results that could have lent
themselves better to meta-analysis would be to have a hazard ratio
for risk to decline in QoL, although this would require setting an
arbitrary cut-off value.
Central pathology review was only used in selected studies (BR12
2010; EORTC/NCIC 26981-22981; NOA-08 2012; Nordic
2012). Variation in pathological diagnoses between treatment
arms at baseline could be a significant confounding variable i.e.
a disproportionate number of lower grade tumours would be ex-
pected to improve survival in that arm independently of treat-
ment. Inter-observer variations in the interpretation of the his-
tology is known to exist with concordance rates between experi-
enced neuro-pathologists of between 81% to 90% when histolog-
ical typing and grading of neuro-epithelial tumours is concerned
and higher when diagnosing other types of brain tumours (Castillo
2004; Velasquez-Perez 2002).
Strict definitions for recurrence are important for determining
PFS and in recruiting patients for trials of therapy in recurrent
disease. When only radiological criteria are used for diagnosis of
recurrence this is known to be inadequate and will include some
who do not have recurrence but changes due to treatment (Wen
2010). Open and thorough criteria should be used to define re-
currence according to clinical symptoms, imaging or increasing
steroid therapy: the ’Macdonald criteria’ (with subsequent update)
can be considered as the accepted standard (Wen 2010). Only four
trials included included adequate definitions of recurrence (BR12
2010; Clarke 2009; Nordic 2012; NOA-08 2012).
Pharmaceutical companies were essentially involved with all the
trials to some degree (specifically: Schering-Plough;Merck;Merck
Sharp&Dohme; and ESSEX Pharma®). This was through either
links to certain authors or direct sponsorship of the trial. In most
cases it was emphasised that the pharmaceutical companies had
no other role in trial design or data analysis.
Effects of interventions
Primary concomitant/adjuvant therapy
Three studies were included with 745 patients in total (
Athanassiou 2005; EORTC/NCIC 26981-22981; Kocher 2008).
Temozolomide resulted in an increase in survival (HR 0.60, 95%
CI 0.46 to 0.79, P value 0.0003 (Analysis 1.1)) compared with
radiation only. Random-effects models were used but the overall
effect size was similar using fixed-effect models. Significant inter-
trial heterogeneity was suggested (P value 0.11; I² = 55%). This
may partially be explained by study design: the two trials investi-
gating temozolomide therapy in both concomitant and adjuvant
phases (Athanassiou 2005; EORTC/NCIC 26981-22981) gave
results that were strongly in favour of temozolomide (pooled HR
= 0.56, 95% CI 0.42 to 0.74), whereas results from the single
trial using temozolomide in the concomitant phase only (Kocher
2008) were equivocal (HR = 0.89, 95% CI 0.49 to 1.61). Never-
theless, when the trials were stratified according to this character-
istic, there was insufficient evidence to reject a null hypothesis of
homogeneous strata (P value 0.17; I² = 47.8%).
Similar results were seen for PFS (Analysis 1.2). Across all three
trials, a significant benefit in favour of temozolomide was observed
(HR = 0.63, 95% CI 0.43 to 0.92). Again, there was clear evi-
dence of inter-trial heterogeneity (P value 0.03; I² = 71%) but,
in this analysis, experimental design was an even more convinc-
ing explanation of statistical heterogeneity. The two concomitant
and adjuvant trials gave strong and congruent estimates of PFS
extension with temozolomide (pooled HR = 0.54, 95% CI 0.46
to 0.64; heterogeneity: P value 0.47; I² = 0%). In contrast, the trial
using temozolomide in the concomitant phase only found no such
benefit (HR = 1.06, 95% CI 0.65, 1.75), and a stratified meta-
analysis was strongly suggestive of a statistical difference between
the two approaches (P value 0.01; I² = 84.2%).
Taken together, evidence for OS and PFS suggest that the use
of temozolomide concomitantly and adjuvantly to radiotherapy
results in extended survival, when compared with radiotherapy
alone. However, a similar benefit has not been demonstrated when
temozolomide therapy is confined to the concomitant phase only.
For QoL the results from the single included RCT are presented
descriptively (EORTC/NCIC 26981-22981). A total of 490 of
573 patients were suitable after baseline analysis. At first follow-
up, groups differed only in social functioning, favouring the ra-
13Temozolomide for high grade glioma (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
diotherapy-only group. There was no difference between the two
arms for any of the seven outcomemeasures (overall, fatigue, social
function, emotional function, future uncertainty, insomnia and
communication deficit). Overall baseline health-related quality of
life (HRQoL) was substantially impaired compared with controls
but not between arms.
Data for adverse events (Analysis 1.3) were complete but for only
grade 3 or 4 toxicity in one trial (EORTC/NCIC 26981-22981)
and only incomplete outcomes were reported in another (Kocher
2008). Only selected grade 3 to 4 toxicity was analysed: detailed
results are presented inCharacteristics of included studies. A statis-
tically significant increase in risk was found in the temozolomide
arm for haematological (odds ratio (OR) 8.09, 95% CI 4.69 to
13.97), fatigue (OR 1.98, 95% CI 1.15 to 3.41), and infections
(OR 2.45, 95% CI 1.15 to 5.23) but not for thromboembolic
events (OR 0.74, 95% CI 0.35 to 1.58).
Temozolomide versus radiotherapy in the elderly
Two studies were included with 664 patients randomised (Nordic
2012; NOA-08 2012). For OS, temozolomide alone did not re-
sult in a significant difference versus hypofractionated radiother-
apy alone based on a single trial (Nordic 2012) of 242 patients
(HR 0.82, 95% CI 0.63 to 1.07, P value 0.14, Analysis 2.1) or
versus standard radiotherapy based on two trials of 566 patients
(HR 0.88, 95% CI 0.57 to 1.36, P value 0.56, Analysis 2.2). In
the latter analysis significant heterogeneity was demonstrated be-
tween the trials (I2= 0.84%, P value 0.01) which may be due to
one trial being designed as a non-inferiority study. Data on PFS
was only available for a single trial of 373 participants comparing
temozolomide alone with standard radiotherapy (NOA-08 2012)
and did not demonstrate a difference between arms (HR 1.15,
95% CI 0.92 to 1.44, P value 0.22, Analysis 2.3). Adverse events
data (greater than grade 2) demonstrated significantly higher risk
with temozolomide of neutropaenia, thrombocytopaenia, lym-
phocytopaenia, infections, thromboembolic events, nausea/vom-
iting and overall adverse events (OR 3.18, 95% CI 1.81 to 5.58, P
< 0.0001, Analysis 2.4). There was no difference for pancytopae-
nia, fatigue, seizures or cutaneous effects. In general the rates of
adverse events were more frequent in one of the trials than the
other introducing significant heterogeneity (I2 87%, P < 0.0001).
For QoL the data is presented in a descriptive fashion. In one trial
health-related quality of life was similar in both groups for the
82% of patients that data was available (NOA-08 2012). In the
second trial again the ratings for global health status were similar
between arms it was reported that patients in the temozolomide
arm generally reported better QoL (Nordic 2012). However, there
was significant attrition with data available for only 83% at base-
line, 59% at 6 weeks, 44% at 3 months, and a low enough return
at 6 months to effectively preclude meaningful analysis.
Different temozolomide dosing schedules
A single RCT of 85 patients compared dose-dense temozolo-
mide versus metronomic temozolomide as primary therapy for
GBM (Clarke 2009). Overall survival was not statistically differ-
ent between arms (HR 0.84, 95% CI 0.50 to 1.41, P value 0.51)
(Analysis 3.1). No data on PFS or QoL were reported in this trial.
Adverse events were incompletely recorded with regard to total
haematological events, infections and thromboembolism. Individ-
ual adverse events were limited by low numbers but lymphopaenia
(OR 5.09, 95% CI 2.12 to 12.18, P value 0.0003) and overall
adverse events (OR 2.12, 95% CI 1.15 to 3.91, P value 0.02]
were more common with metronomic than dose dense therapy
(Analysis 3.2).
Therapy for recurrent disease
Two studies were included with 672 patients in total (BR12 2010;
Yung 2000a). Temozolomide did not improve OS for grade III
and IV tumours (HR 0.90, 95% CI 0.76 to 1.06, P value 0.2)
including the grade IV tumour only subgroup (HR 0.87 95% CI
0.65 to 1.16) (Analysis 4.1). There was no heterogeneity between
trials (Chi² = 0.06, df = 1 (P value 0.80); I² = 0%).
Temozolomide was associated with a significant extension of PFS
in the trial conducted in participants with grade IV tumours only (
Yung 2000a;HR0.68 (95%CI0.51 to 0.90)), whereas evidence in
the trial that enrolled people with all high-grade gliomas i.e. grade
III and IV tumours (BR12 2010) did not conclusively demonstrate
a benefit (HR = 0.89 (95% CI 0.73 to 1.09)). When pooled into
a single meta-analysis, this difference leads to expected statistical
heterogeneity (P value 0.13; I² = 56%). The pooled effect estimate
depends critically on themodel used: a fixed-effectsmodel suggests
that temozolomide is associated with significant PFS benefit (HR
= 0.81 (95% CI 0.69 to 0.96); P value 0.01); however, when a
random-effects synthesis is used, the confidence interval broadens,
becoming consistent with a null effect (HR = 0.79 (95% CI 0.61
to 1.03); P value 0.08).
Two studies were included with 553 of 609 participants providing
data on QoL (BR12 2010; Yung 2000a). The results are presented
descriptively in light of the difficulties in integrating QoL data
into a meta-analysis.
• Yung 2000a: At six months of treatment, patients who were
free of progression reported either an improvement of
maintenance of all the preselected health related QoL domain
scores. Patients with disease progression by six months usually
experienced improvement prior to progression, but there was a
sharp decline in most of the preselected domains at progression.
• BR12 2010: At 24 weeks, the mean QoL scores were 51.9
for PCV versus 59.8 for temozolomide (P value 0.038). The
percentage of patients with a 10-point improvement from
baseline to 24 weeks was more marked in the TMZ-5 group
(TMZ-5 (49%) versus TMZ-21 (19%), P value = 0.005; TMZ-
5 (49%) versus PCV (23%), P value = 0.007).
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Adverse events were reported in two trials but only incompletely
(BR12 2010; Yung 2000a). No statistically significant increase in
the risk of adverse events with temozolomide was documented for
any adverse events (OR 1.53, 95% CI 0.81 to 2.89), haematolog-
ical (OR 1.01, 95% CI 0.61 to 1.65) or fatigue (OR 1.5, 95% CI
0.26 to 8.82) (Analysis 4.3).
Funnel plots do not support evidence of publication bias although
the total number of included studies is low (Figure 4).
Figure 4. Funnel plot of comparison: 2 Recurrence Therapy, outcome: 2.1 Survival.
D I S C U S S I O N
Summary of main results
This review found that temozolomide increased overall survival
(OS) and progression free survival (PFS) when used as part of
concomitant and adjuvant primary therapy for GBM: insufficient
data are available for other forms ofHGG (e.g. grade III glioma) as
primary therapy . From the individual trial data, median survival
is estimated to be around 14 months with temozolomide with a
two-month increase over radiotherapy alone. Analysis of the indi-
vidual Kaplan-Meier plots suggests this benefit is mostly after six
months. Adverse events were more common with temozolomide
but drop outs were low suggesting that the clinical management
of adverse events was sufficient to control the symptoms. Long-
term data are minimal and there is the concern that combination
treatment of chemo-radiotherapy may result in significant long-
term toxicity although this has to be balanced with the poor OS in
HGG. It is important to remember that patients were randomised
after surgery and only included if their disease was stable and per-
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formance status (WHO/KPS) of an appropriate level to consider
further therapy. The median survival times seen are likely to be
higher than in series randomising patients prior to surgery due to
the exclusion of aggressive disease and post-operative deaths.
In the elderly, temozolomide alone results in similar survival times
when compared to standard or hypofractionated radiotherapy.
There was significant heterogeneity between the studies with one
trial being of non-inferiority design (NOA-08 2012): when the
survival figures were analysed without including this study temo-
zolomide alone resulted in improved survival compared to stan-
dard dose radiotherapy. Progression-free survival appeared similar
between temozolomide alone versus standard dose radiotherapy
alone but this was only based on the single study of non-inferior-
ity design. Quality of life data suffered from significant attrition
but in general it did not appear to be significantly different be-
tween arms. Adverse events were more common with temozolo-
mide alone than either radiotherapy regimen.
In recurrent disease, temozolomide was not effective in terms of
OS but improved PFS in GBM compared to nitrosourea based
chemotherapy. Data on QoL, however, suggested that temozolo-
mide resulted in maintenance or improvement in scores prior to
recurrence, improved overall scores and a greater percentage of pa-
tients improving, particularlywith the less intensive temozolomide
regimens. Adverse events again were not more common between
arms although theywere incompletely reported. Despite the broad
entry criteria fewer patients will be suitable for chemotherapy in
the recurrent disease setting due to poor performance status.
Overall completeness and applicability of
evidence
When considering the applicability of these findings to patients
in clinical practice, it is important to remember that the patients
enrolled were highly selected, enrolling mainly young and fit pa-
tients. A proportion or patients will also be excluded after surgery
due to post-operative complications or aggressive disease. Sub-
group analysis from the individual trials suggests that young and
fit patients undergoing resection rather than biopsy benefit the
most (EORTC/NCIC 26981-22981). Therapy after recurrence
was also aggressive, with a high proportion undergoing further
surgery or chemotherapy, and this needs to be bourne in mind
when considering the applicability of these results in day-to-day
clinical practice (see table of external validity Table 2).
Molecular markers, specifically MGMT promotor methylation,
have been proposed as a means of predicting those who respond
best to temozolomide. Studies that have analysedMGMT promo-
tor methylation status (EORTC/NCIC 26981-22981; NOA-08
2012; Nordic 2012) have in general found improved response
and survival with temozolomide in those with methylation of the
MGMT promotor compared to those without. Additionally, in
the elderly it has been suggested that MGMT promotor methy-
lation can be used to stratify treatment, whereby in patients that
have MGMT promotor methylation temozolomide alone should
be used, while in patients that are unmethylated radiotherapy
alone is more appropriate. Applicability of such data is limited,
however, by several factors including: data on MGMT promotor
methylation status is usually only available for an incomplete and
non-randomised subgroup of the overall trial population; MGMT
subgroup end-points are usually secondary rather than the pri-
mary outcome of the trial leading to issues with under-powering;
and technical difficulties in assessing MGMT methylation status
with possible heterogeneity between laboratories in the results and
techniques used (although to some extent this can be minimised
by central testing). Analysis of the relevance of MGMT promo-
tor methylation testing should ideally be performed as part of a
Cochrane diagnostic test accuracy review in order to determine
sensitivity, specificity, optimal testing modality, influence on treat-
ment decisions, effect on clinical outcomes, and cost-effectiveness.
Quality of the evidence
Although these findings are generally in favour of temozolomide
there are some reservations with the quality of the data from the
RCTs. Themajor concern is the lack of blinding or placebo control
in all of the included trials which could lead to detection bias with
QoL, PFS and adverse event reporting. There could also be a bias
with post-intervention therapy between arms which in turn could
in turn effect OS. All of the studies assessed included some form
of industry sponsorship although it was emphasised that this did
not interfere with the actual trial process itself and probably did
not introduce a further source of bias. Optimal reporting methods
for RCTs should focus on: clarifying methods of allocation con-
cealment; clear reporting of hazard ratios and confidence intervals
for all time-to-event data; clearly presenting QoL; objective def-
initions of recurrence; standardised care pathways for managing
recurrent disease and post-intervention therapy.
Longitudinal data on QoL were only reported in one trial. Al-
though the questionnaires and methodology used were excellent
data, the expected difficulties in obtaining complete data sets
(Walker 2003) puts this study at significant risk of attrition bias.
Other limitations include selective reporting and only including
data up until progression.
Potential biases in the review process
In the elderly, variability between the studies in terms of the pa-
tients included and interventions performed could lead to con-
cerns over appropriate pooling of the studies into a meta-anal-
ysis. Specifically the age range cut-offs demonstrated some het-
erogeneity in whether they assessed elderly as being over 60
(Nordic 2012), 65 (NOA-08 2012), or 70 (EORTC/NCIC
26981-22981). Temozolomide schedules also varied depending
onwhether it was given as either standard therapy, dose-intensified
therapy, concomitant and adjuvant or only concomitant therapy.
Radiotherapy schedules could be either standard or hypofraction-
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ated. We deemed it appropriate to pool these studies in light of
their being little proven difference with the variations in each of
the interventions but also performed sub-group analyses which
could have lead to issues with multiple comparisons and small
treatment groups.
Incorporation of QoL into meta-analysis is hindered by multiple
analyses, variable definitions, repeated testing and high numbers
of drop outs. Although the study reported that QoL was much the
same between groups, this did not reflect the significant impair-
ment that both arms had with controls at baseline and the marked
deterioration at disease progression. Interpretation of this data is
most valuable in confirming that therapy with temozolomide does
not appear to be detrimental to QoL.
Agreements and disagreements with other
studies or reviews
Previous studies have suggested that conventional standard radio-
therapy is not well tolerated in the elderly and that hypofraction-
ated radiotherapy is better in terms of overall survival (OS) com-
pared to best standard care (ANOCEF 2007). Our finding that
temozolomide alone is better than standard radiotherapy but not
hypofractionated radiotherapy is in keeping with this belief. Ad-
ditionally, sub-group analysis from the individual trials indicates
a high proportion of patients allocated standard radiotherapy fail
to complete the full treatment schedule (Nordic 2012). The main
RCT for standard radiotherapy with concomitant and adjuvant
temozolomide found that although in the complete treatment
population of those aged 18-70 temozolomide was efficacious but
that this advantage decreased with age particularly in those over 65
(EORTC/NCIC 26981-22981). In general, it appears that elderly
patients do not tolerate standard dose radiotherapy, but do benefit
from anti-tumour therapy with either hypofractionated radiother-
apy or temozolomide. A new RCT is currently underway to assess
hypofractionated radiotherapy with concomitant and temozolo-
mide versus temozolomide alone in patients over 65 with GBM
(NCT0048267).
Other means of delivering chemotherapy in HGG include im-
plantation of wafers coated with carmustine (Gliadel®) onto the
resection cavity wall at the time of resection or systemic nitrosourea
based chemotherapy (PCV). Compared with these treatments, the
median survival with temozolomide is similar to that seen in a
meta-analysis of Gliadel® (Hart 2011b) and in a meta-analysis of
PCV chemotherapy (GMTGroup 2002). Gliadel® also has a low
incidence of adverse effects but PCV therapy is potentially toxic.
Data on TTP and QoL are more limited than that with temozolo-
mide. Gliadel® is expensive and not all patients will be suitable
due to anatomic and other surgical considerations. Decisions over
which therapy is to be recommended in an individual patient are
best taken in a multidisciplinary setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For primary therapy of glioblastoma multiforme (GBM), temo-
zolomide is effective when used as primary therapy compared with
radiotherapy alonewhenused in a concomitant and adjuvantman-
ner. It prolongs survival and progression-free survival (PFS) but
with an increased risk of early adverse events. These results are
based on three randomised controlled trials (RCTs) of 745 patients
in total. A single RCT did not find any difference in survival with
either dose-dense or metronomic temozolomide schedules for pri-
mary disease. There are no data on other high grade gliomas (e.g.
grade III glioma).
In the elderly population, temozolomide alone is comparable to
hypofractionated radiotherapy in terms of overall survival (OS),
although adverse events appeared to be more common. Temozolo-
mide alone results in better OS and time to progression (TTP)
compared with standard dose radiotherapy which appears to be
poorly tolerated. Although quality of life (QoL) data is limited
there does not appear to be a significant difference between the
two treatments. Either temozolomide alone or hypofractionated
radiotherapy could be recommended as first line treatment op-
tions depending on patient preferences for follow-up, monitoring
and adverse events.
In recurrent HGG, temozolomide improves PFS (in the subgroup
of grade IV tumours only) and may have beneficial effects on QoL
but does not improve OS. There are still some reservations with
these data as the trials were not blinded or placebo controlled
while quality of life data could be further expanded upon. In a well
selected subgroup of patients with GBM, temozolomide warrants
consideration for use as initial therapy, but decisions need to be
made on an individual patient basis as part of a multidisciplinary
meeting discussion.
Implications for research
Further trials are needed with improved methodology, includ-
ing placebo control, blinding, and the use of clear statistical re-
porting of outcome measures, particularly QoL. Dose intensifi-
cation schedules or combination therapies present room for ex-
ploration as a means of decreasing resistance to therapy. A trial
comparing Gliadel® either in comparison or combination with
temozolomide is warranted in light of the similar survival bene-
fits in a comparable patient populations. Application of molecu-
lar marker (e.g. MGMT promotor methylation) testing in order
to predict response to temozolomide is an active area of research
which could prioritise treatment to only those who are expected to
benefit; ideally definitive assessment should be performed as part
of a Cochrane diagnostics test accuracy review. Extrapolation of
the findings from the highly selected patients enrolled in RCTs to
’real world’ situations is urgently needed to confirm the external
validity of these findings
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Athanassiou 2005
Methods Single centre randomised phase II study
Participants Total of 130 patients, 110 subsequently used for analysis. Inclusion criteria: age over 18,
Grade IV tumour and KPS > 60. Exclusion criteria: “poor medical condition because
of non-malignant systemic disease or acute infection”; any medical condition that could
interfere with oral administration of TMZ
Interventions It used a dose intensification schedule of temozolomide in the adjuvant phase involving
150 mg/m2 temozolomide on days 1 to 5 and days 15 to 19 for a maximum of 6 cycles.
In the concomitant phase temozolomide was administered using a standard 75mg/m2
daily dose throughout. Radiotherapy was administered to both arms in a dose of 60 Gy
over 6 weeks
Outcomes Primary: Survival; PFS. Secondary: Safety
Notes Survival: median TMZ 13.41 months (95%CI 9.53 to 17.13) versus control 7.7months
(95% CI 5.32 versus 9.2 months), log rank P,0.0001). Survival percentages at 6, 12 and
18 months.
TTP: TMZ 10.8 months (95% CI 8.08 to 14.69), log rank P < 0.0001. TTP survival
percentages at 6, 12 and 18 months.
Cox proportional hazards model (including age, extent of surgery, KPS and treatment
group) for OS and TTP. Administration of TMZ and KPS were significant prognostic
factors.
Subgroup analysis for poor performance status group: non-significant for OS or TTP.
Toxicity: concomitant TMZ Grade 3/4 leucopenia 3.5% and thrombocytopenia 5.2%,
adjuvant TMZ leucopenia 2% and thrombocytopenia 5%. Non-haematological side
effects: rash 5%, constipation 3.5%, arthralgia 1.5%
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not specified in article
Allocation concealment (selection bias) Unclear risk Not specified in article
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded = not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded = not applicable
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Athanassiou 2005 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded = not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
BR12 2010
Methods Multicentre RCT based in the UK. Randomisation was via phone to the MRC clinical
trials unit. Treatment allocation used minimization with stratification factors of centre,
tumour grade (3 or 4 or high grade unspecified), and PS (0 or 1 v 2 or 3) across all
three groups. The primary comparison on which the study was powered was TMZ (both
schedules combined) versus PCV. With 380 deaths from approximately 500 patients
randomly assigned over 3 to 4 years, the study had 80% power to detect a 2-month
increase in median survival (HR, 0.75) and 90% power to detect a 3-month increase
(HR, 0.67), with a two-sided significance level of P 0.05. We assumed that at least two
thirds of patients had GBM (grade 4), giving 80% power to detect a similar difference
in survival in a planned subgroup analysis of such patients
Participants 447 patients between 2003 and 2007. Inclusion criteria were an interval of over 2months
since completing primary therapy, a life expectancy of over 1 month, adequate baseline
laboratory function and general fitness to commence further therapy. Exclusion criteria
were pregnancy, oligodendroglial histology, a WHO score of 4 (Table 3), and previous
chemotherapy, radiosurgery or brachytherapy.
Interventions The treatment arm consisted of either TMZ 200mg/m2 for days 1 to 5 of 28 or TMZ
100mg/m2 for days 1 to 21 of 28 (’dose dense’). The control arm consisted of PCV (at
standard doses) every 6 weeks until progression or 6 cycles in total
Outcomes OutcomeswereOS, PFS, andQoL.Definitionswere given for recurrence (multifactorial)
and QoL
Notes OS: HR 0.91 (0.74 to 1.11) P value 0.35
PFS: HR 0.89 (0.73 to 1.08) P value 0.23
QoL: at 24 weeks themeanQoL scores were 51.9 for PCV versus 59.8 for TMZ (P .038)
and 64.3 for TMZ-5 versus 54.4 for TMZ-21 (P 0.036), with a significant difference
also seen between PCV and TMZ-5 (51.9 v 64.3, respectively;
P 0.006). The percentage of patients with a 10-point improvement from baseline to 24
weeks was more marked in the
TMZ-5 group (TMZ-5 v TMZ-21: 49% v 19%, respectively; P 0 .005; and PCV v
TMZ-5: 23% v 49%, respectively; P 0.007)
Adverse events (grade 3/4 whole treatment period): PCV 16.4%, TMZ-5 18.9%, TMZ-
21 14%
Risk of bias
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BR12 2010 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk Non-blinded study - not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Non-blinded study - not applicable
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Non-blinded study - not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
Clarke 2009
Methods Single centre (MSK NYC USA) randomised controlled non-blinded study. Stratified
by random permuted block method using Simon’s 2 stage minimax design. Patients
stratified at entry. Powered to a historical control. ITT
Participants A total of 85 patients between 2005 to 2007. New diagnosis of GBM on pathology.
Inclusion criteria: age 18 to 70, KPS >= 60. Exclusion criteria: other cancer, baseline
labs, pregnant, nursing (presumed to mean under in-patient care)
Interventions Treatment: all patients received radiochemotherapy with RTx (60 Gy) +/- IMRT +Temo
75mg/m2 daily. The ’dose dense’ arm received 150mg/m2 on days1-7 & 15 to 21 of
every 28 days cycle. The ’metronomic’ arm received 50mg/m2 on days 1 to 28 of every
28 days cycle. Also 13-cis-retinoic acid was given as maintenance therapy to both arms
Outcomes Outcome: OS, progression-free survival (with MacDonald criteria & MRI every 2
months with definitions for pseudo-progression). Adverse events according toNCI CTC
(version 3.0)
Notes Median survival: dose dense 17.1 (14.0 to 28.1) months versus metronomic 15.1 (12.3
to 18.9) months
PFS: dose dense 6.6 months versus metronomic 5.0 months
Adverse events (total number of grade 3/4): dose dense = 31 versus metronomic 28
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Clarke 2009 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not clearly stated in the article
Allocation concealment (selection bias) Unclear risk Not clearly stated in the article
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded - not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded - not applicable
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded - not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
EORTC/NCIC 26981-22981
Methods Central randomisation over the phone or the internet from EORTC headquarters. Strat-
ified by WHO status, type of surgery & institution. Minimisation technique based on
variance method with semi-random assignment. Power: 80% at 0.05 significance for
33% increase (HR 0.75) in median survival
Participants Inclusion criteria were: age between 18 to 70, stable steroid requirements, adequate
baseline blood tests, and a WHO performance score of 2 or less (Table 3). Exclusion
criteria were not specified. Histology was centrally verified. MGMT status was recorded
retrospectively on PCR
Interventions Standard radiotherapy schedules of 60Gy for 6 weeks was given to both arms. The
treatment arm comprised of TMZ 75mg/m2 daily during radiotherapy then up to 6
adjuvant cycles of 150 to 200mg/m2 for 1 to 5 out of every 28 days for a total of 6 further
cycles. No routine chemotherapy was given to the control arm. Subsequent management
was given according to need with no pre-specified protocol mentioned
Outcomes The primary end point was OS; secondary endpoints included progression-free survival,
safety andquality of life (reported separately - seeTaphoorn2005).Definitionswere given
for progression (radiological or increasing steroids), extent of surgery (surgeons opinion)
and adverse events (NCI CTC). Follow-up was at baseline, 28 days after completing
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EORTC/NCIC 26981-22981 (Continued)
radiotherapy, and thereafter at 3 monthly intervals
Taphoorn 2005
EORTCQLQ-C30 andQLQ-BN20. Itemswere scaled and scored according to standard
practice. Raw scores were converted to a linear range of 0 to 100 with higher scores
reflecting higher functioning or symptoms. To account for multiple testing and based on
prior knowledge seven criteria were pre-specified for analysis. Differences of 10 points
were considered clinically significant: smaller differences were disregarded. Assessments
were performed prior to treatment, at week 4 of radiotherapy, 4 weeks after completion
of radiotherapy, at the end of the 3rd and 6th cycles of adjuvant TMZ, and every 3
months thereafter until disease progression. Prior guidelines were followed with regard
to reporting
Notes Survival: median TMZ 14.6 months (95% CI 13.2 to 16.8) versus Control 12.1 months
(CI 11.2 to 13), HR 0.63 (95% CI 0.52 to 0.75) P < 0.001 log rank test. Also survival
at 6 monthly intervals up to 24 months.
Progression-free survival: TMZ 6.9 months (95% CI 5.8 to 8.2) versus Control 5.0
months (4.2 to 5.5), HR 0.54 (95% CI 0.45 to 0.64) P < 0.001 log rank test. Also
progression-free survival at 6 monthly intervals up to 24 months.
Cox proportional hazards model (including age, corticosteroid use, sex, MMSE score
and tumour location): HR 0.62 (95% CI 0.51 to 0.75).
Subgroup analyses: survival advantage maintained in all subgroups analysed except those
undergoing biopsy and those with poor performance score
Safety: TMZGrade 3/4 haematologic toxicity in concomitant phase 7%, adjuvant phase
14%, entire study period 16%, and leading to treatment discontinuation in 5%. No
haematologic toxicity in control arm. Results for TMZ versus control were: severe infec-
tions 3% versus 2%; fatigue 33% versus 26%; and thromboembolic events 3% versus
2%
Stupp 2009
Survival: HR 0.63 (0.53 to 0.75) P < 0.0001
PFS: HR 0.56 (0.47 to 0.66) P < 0.0001
Adverse events (late toxicity grade 3/4): treatment = 3 patients, control = 1 patient
Taphoorn 2005
Follow-on paper describing only the quality of life results from the initial trial run by
the EORTC.
No significant difference in HRQoL between TMZ and control arms
490 of 573 patients after baseline analysis
Assessments restricted to first 4 assessments (compliance similar between arms until this
point)
Overall baseline HRQoL was substantially impaired compared with controls but not
between arms
At first follow-up, groups differed only in social functioning, favouring the radiotherapy-
only group
Over subsequent assessments, HRQoL was much the same between treatment groups
Risk of bias
Bias Authors’ judgement Support for judgement
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EORTC/NCIC 26981-22981 (Continued)
Random sequence generation (selection
bias)
Low risk
Allocation concealment (selection bias) High risk Not blinded = not applicable
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded = not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded = not applicable
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded = not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk
Selective reporting (reporting bias) Low risk
Kocher 2008
Methods Randomised non-blinded non-placebo controlled trial. Power was 80% at 5% signifi-
cance for 10% improvement in PFS at 9 months (HR 0.75). Randomisation was via
telephone
Participants A total of 65patients from11 centreswere randomised between2002 and2004. Inclusion
criteria: age 18 to 70, unifocal GBM, macroscopic tumour resection (based on early CT/
MRI), PS 0-2, stable labs. Exclusion criteria: recurrent disease, prior therapy, other major
medical illness or infection, previous malignancy, pregnancy. 5 patients lost to follow-up
Interventions Both arms received radiotherapy involving 60 Gy in 2.0 Gy daily fractions 5 days per
week for 6 weeks. Treatment arm: TMZ 75mg/m2 on days 1 to 28 concomitant with
radiotherapy only. No adjuvant TMZ. Control arm: no further therapy (other than
radiotherapy)
Outcomes Outcomes: OS, PFS and toxicity. Follow-up included clinical assessment, WHO score,
QoL questionnaires, and MRI at least 3 monthly
Notes Adverse events (grade 3/4): treatment arm - nausea 32% (4%), lymphopenia 58% (33%)
, elevated liver enzymes GPT 57% (7%) and 40% (4%) versus control arm - nausea 3%
(3%), lymphopenia 21% (6%), elevated liver enzymes GPT 15% (3%) and GOT 3%
(0%)
PFS: treatment 6.3 (5.1-7.5) months versus control 7.6 (6.8 to 8.4) months (P value 0.
801) HR = 0.94 (95% CI 0.6 to 1.6)
OS: treatment 14.6 (11.3 to 18.0) months versus control 17.1 (13.5 to 20.8) months
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Kocher 2008 (Continued)
(P value 0.668) HR = 0.89 (95% CI 0.5 to 1.6)
QoL: ’for both general and brain-related quality of life, better scores were observed at
nearly all points of time in the RT + TMZ group: before therapy, the scores were similar
in both groups’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated in article
Allocation concealment (selection bias) Unclear risk Not clearly stated in article
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded = not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded = not applicable
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded = not applicable
NOA-08 2012
Methods Randomised phase III trial. Randomisation was performed centrally by an independent
contract research organisation. A list was generated electronically in block of variable
length without stratification with allocation 1:1 before the start of the study
Participants Inclusion criteria were: de-novo anaplastic astrocytoma or glioblastoma that was his-
tologically confirmed locally after biopsy or resection; age older thatn 65 years; and a
Karnofsky performance score of 60 or more. Central histological review was performed.
Exclusion criteria were: patients having undergone previous systemic chemotherapy or
radiotherapy to the brain; inadequate bone marrow reserve, liver function or renal func-
tion
Interventions Temozolomide: 1 week on / 1 week off schedule, 100mg/m2 on days 1-7, with increases
or decreases of 25mg/m2 depending on blood counts and tolerability.
Radiotherapy: to gross tumour volume plus a 2cm margin over 6-7 weeks in fractions
of 1.8-2.0 Gy to a total of 60.0 Gy according to preoperative MRI and dedicated CT or
three-dimensional planning systems
Outcomes Tumour response was defined by theMacdonald criteria.MGMTpromotor methylation
was assessed by two distinct methylation-specific PCR assays
Primary endpoint: overall survival.
Secondary endpoints: event-free survival, best response, QOL, and safety
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NOA-08 2012 (Continued)
Notes Minimum follow-up 12 months.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central electronic randomisation by an in-
dependent organisation
Allocation concealment (selection bias) Low risk Allocations were revealed by fax transmis-
sion to a project manager
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding or placebo used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding or placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding or placebo used
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysis was on an intention-to-treat ba-
sis with all withdrawals and protocol vio-
lations clearly specified. There was a high
rate of drop-outs for quality of life data in
keeping with other studies making it a high
risk of bias
Selective reporting (reporting bias) Low risk All pre-specified outcomes were reported.
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Nordic 2012
Methods This was a randomised, controlled phase 3 study involving 28 predominantly European
oncology centres enrolling 342 patients between 2000 and 2009. It focused on patients
over 60 years old with a histologically confirmed WHO grade IV astrocytoma. The
primary hypopthesis was to test if chemotherapy wth temozolomide was better than
hypofractionated radiotherapy (the current standard of care for elderly patients) but with
an improved quality of life profile
Power calculation for 480 patients with 160 per treatment group for 10% survival
difference (10-20% at 1 year). 90% power at 5% significance via the log rank
Sponsors had no role in study design, data collection, data analysis, data interpretation,
or writing of the report
Randomisationwas by computer. Patients were randomised depending on the institution
to either: 1:1:1 in blocks of 9 to either temozolomide, hypofractionated radiotherapy,
or standard radiotherapy; or in blocks of 8 to either temozolomide or hypofractionated
radiotherapy. Blinding was not used
Participants Additionaly inclusion crieria were: WHO performance scores 0-2 (or 3 if a neurological
deficit); adequate haematological, renal and liver function; and were expected by the
doctor to tolerate all treatment options. After 2004 patients deemend fit to receive com-
bination treatment were exlcuded based on the results of another trial (EORTC/NCIC
26981-22981). Exclusion criteria were: another primary cancer; WHO performance
score 3-4; any disorder likely to interfere with study treatment; previous therapy for a
brain tumour; and previous radiotherapy to the head that would prevent further irradi-
ation
Interventions Temozolomide was administered orally in 200mg/m2 doses on days 1-5 of every 28 days
for up to six cycles or until radiological progression, clinical progression, or both, unac-
ceptable adverse effects were seen, or until a physcician or patient chose to discontinue
treatment. Hypofractionated radiotherapy was administered in 6 fractions of 5.0 Gy for
3 days a week over 2 weeks or 34.0 Gy delovered in 10 fractions of 3.4 Gy on 5 days a
week over 2 weeks. Standard radiotherapy was 60.0 Gy in 30 fractions of 2.0 Gy over 6
weeks
Outcomes Outcome measures were: QOL EORTC QLQ-30 and BN20. Assessments were at 6
weeks, 3 months, 6 momths. AE via the WHO grading system except nausea and
vomiting by the NCIC version 2.0 Further therapy at discretion
Central pathologywith IDH1 andMGMTviaDNA isolated paraffin embedded tumour
quantitative methylation specific PCR normalised to beta-actin (ACTB) with a ratio of
>2.0 being positive
Notes Survival: temozolomide versus hypofractionated radiotherapy (n=242). HR 0.82 (0.63-
1.06) p=0.12, median survival 8.4 months (7.3-9.4) versus 7.4 (6.4-8.4), 25% at 1 year.
Subgroup over 70 benefitted from temozolomide
QOL: 284/342 (83%) at baseline, 59% at 6 weeks, 44% at 3 months. Generally better
with temozolomide althoug no change for global health status
Adverse events: Temozolomide - neutropaenia 12%, pancytopaenia 2%, thrombocy-
topaenia 21%, infection/fever 19%, VTE 7%, ICH 3%, bleeding 2%, seizures 7%, fa-
tigue 4%, nausea 7%, vomiting 3%. Hypofractinated - infection/fever 7%, VTE 6%,
bleeding 2%, seizures 7%, fatigue 6%, vomiting 1%. Standard - infection/fever 14%,
VTE 2%, ICH 3%, bleeding 1%. seizures 13%, fatigue 6%, nausea 5%, vomiting 2%
MGMT; available in 258/342 (75%) but 55 (21%) not evaluatable. Methylated in 91/
30Temozolomide for high grade glioma (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Nordic 2012 (Continued)
203 (78%)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated allocation from a cen-
tral location
Allocation concealment (selection bias) Low risk
Blinding (performance bias and detection
bias)
All outcomes
High risk No blinding or placebo used.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding or placebo used.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding or placebo used.
Incomplete outcome data (attrition bias)
All outcomes
High risk Very high risk for quality of life data i.e.
83% at baseline, 59% at 6 weeks, 44% at
3 months. Otherwise low risk
Selective reporting (reporting bias) Low risk All pre-specified outcomes reported
Yung 2000a
Methods Randomised multicentre phase II study
Participants 225 patients from multiple international centres. Inclusion criteria: known GBM at
first relapse, age of 18 or more, KPS of 70 or more, life expectancy of 12 weeks or
more. Exclusion criteria: more than one prior chemotherapy; previous chemotherapy
with single agent PRO or dacarbazine; vincristine within 2 weeks prior to study drug;
nitrosurea or mitomycin Cwithin 6 weeks prior to study drug; chemotherapy (excluding
vincristine, nitrosurea or mitomycin C) within 4 weeks prior to study drug; history
of PRO-induced rash; pervious interstitial radiotherapy or stereotactic radiotherapy;
pregnancy; breastfeeding; toxicity from prior radiotherapy; HIV positive; previous or
concurrent solid tumour at other sites (excluding basal cell carcinoma)
Interventions Temozolomide: 150 to 200mg/m2 on days 1 to 5 out of a 28 day cycle. Procarbazine 125
to 150mg/m2 for 28 consecutive days in a 56 day cycle. Treament until unacceptable
toxicity, disease progression or 2 years treatment completed
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Yung 2000a (Continued)
Outcomes Objective response, six month PFS, median PFS, survival, adverse events
Osoba 2000a
EORTC QLC-C30 and BCM20. Follow-up was prior to each cycle of chemotherapy.
Scoring was according to standard procedures with conversion to a range of 0 to 100
and higher scores indicating better functioning or more symptoms. To reduce error
due to repeat statistical testing seven criteria were chosen pre-hoc for testing based on
prior knowledge. Changes were assessed at 6 months as well as prior to, and at the time
of, disease progression. The significance of changes was determined by statistics, effect
sizes, and the proportions of patients with an improvement of ten points or more (the
minimum considered clinically significant: smaller changes were disregarded)
Notes Objective response: TMZ 45.6% versus PRO 32.7%, P value 0.049
PFS: median TMZ 12.4 weeks versus PRO 8.32 weeks, HR 1.47 (95% CI 1.11 to 1.
95) P value 0.0063. PFS percentages at 6 months.
Survival: HR 1.11, P value 0.019. Survival percentages at 6 months.
Adverse events. Drop outs due to adverse events, TMZ 3 versus PRO 11. No other
adverse events at greater than 5% in either arm
Osoba 2000a
At 6 months of treatment, patients who were free of progression reported either an
improvement of maintenance of all the preselectedHRQoL domain scores. Patients with
disease progression by 6 months usually experienced improvement in HRQoL prior
to progression, but there was a sharp decline in most of the preselected domains at
progression
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) High risk Not blinded - not applicable
Blinding (performance bias and detection
bias)
All outcomes
High risk Not blinded - not applicable
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded - not applicable
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded - not applicable
Incomplete outcome data (attrition bias)
All outcomes
Low risk Not blinded - not applicable
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Yung 2000a (Continued)
Selective reporting (reporting bias) Low risk
CT = computed tomography; GBM = glioblastoma multiforme; GOT = glutamic-oxaloacetic transaminase (serum enzyme); GPT =
glutamate pyruvate transaminase (serum enzyme); HR = hazard ratio; HRQoL = health-related quality of life; IMRT = intensity-
modulated radiation therapy; ITT = intention-to-treat; KPS = Karnofsky Performance Score; MGMT = O6-methylguanine-DNA
methyltransferase; MMSE = mini-mental state examination score; MRI = magnetic resonance imaging; NCI CTC = National
Cancer Institute Cancer Treatment Criteria; OS = overall survival; PCB or PRO = procarbazine; PCV = procarbazine, lomustine
and vincristine; PFS = progression-free survival; PS = performance status; QoL = quality of life; RCT = randomised controlled trial;
RTx = radiotherapy; TMZ = temozolomide; TTP = time to progression;
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bogdahn 2011 This assessed trabedersen (a TGF B2 antisense oligodeoxynucleotide) in one of two doses delivered through
an intra-tumoural convection enhanced delivery system with best medical care (involving either standard dose
temozolomide or PCV) for recurrent/refractory HGG. Temozolomide was used as the control rather than being
directly assessed
Bower 1997 Phase II study. Non-randomised participants.
Gilbert 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Hamilton 2006 Review, commentary or presentation of an included RCT.
Kim 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Lanzetta 2003 A review on the experiences of temozolomide at a single institution between. No prospective data collection or
randomisation of participants
Lee 2008 Review, commentary or presentation of an included RCT.
Linz 2009 Review, commentary or presentation of an included RCT.
Malmstrom 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Malmstrom 2010b Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Naboors 2009 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Najak 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
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(Continued)
Newlands 1996 A single centre experience at theCharing CrossHospital in London on the use of temozolomide. No prospective
data collection or randomisation of participants
Osoba 2000b Quality of life data on anaplastic astrocytoma from an earlier phase II study - non-RCT
Qian 2009 Incomplete data presentation (i.e. no Kaplan-Meier plots) preventing analysis
Renard 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Spiegel 2007 Meta-analysis rather than RCT.
Stupp 2002 A phase II study. Participants were not randomised. Primary outcomes were safety and toxicity
van den Bent 2009 This assessed the benefit of erlotinib (a tyrosine kinase inhibitor) with temozolomide or carmustine as the
control in patients with recurrent GBM rather than directly assessing the benefit of temozolomide per se
Wang 2010 Meta-analysis rather than RCT.
Weller 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Wick 2009 This RCT tested if initial upfront chemotherapy alone (with either PCV or TMZ) was as efficacious as initial
radiotherapy alone regarding time to treatment failure with a randomisation schedule of 1:1:2.compared.
However individual results for the TMZ arm were not reported prohibiting inclusion in the review
Wick 2010 Abstract of conference proceedings: excluded due to a lack of complete presentation of the final results
Yung 1999 Phase II study. Participants were not randomised/single arm study
Yung 2000b Phase II study. Participants were not randomised.
GBM = glioblastoma multiforme; HGG = high grade glioma; PCV = procarbazine, lomustine and vincristine; RCT = randomised
controlled trial; TMZ = temozolomide
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D A T A A N D A N A L Y S E S
Comparison 1. Primary Concomitant/Adjuvant Therapy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Overall survival 3 745 Hazard Ratio (Random, 95% CI) 0.60 [0.46, 0.79]
1.1 Concomitant and
adjuvant therapy
2 683 Hazard Ratio (Random, 95% CI) 0.56 [0.42, 0.74]
1.2 Concomitant therapy only 1 62 Hazard Ratio (Random, 95% CI) 0.89 [0.49, 1.61]
2 Progression-free survival 3 745 Hazard Ratio (Random, 95% CI) 0.63 [0.43, 0.92]
2.1 Concomitant and
adjuvant therapy
2 683 Hazard Ratio (Random, 95% CI) 0.54 [0.46, 0.64]
2.2 Concomitant therapy only 1 62 Hazard Ratio (Random, 95% CI) 1.06 [0.65, 1.75]
3 Adverse events 2 2353 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.76 [2.02, 3.77]
3.1 Total adverse events 0 0 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.0 [0.0, 0.0]
3.2 Haematological 2 634 Peto Odds Ratio (Peto, Fixed, 95% CI) 8.09 [4.69, 13.97]
3.3 Fatigue 1 573 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.98 [1.15, 3.41]
3.4 Thromboembolic 1 573 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.74 [0.35, 1.58]
3.5 Infections 1 573 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.45 [1.15, 5.23]
Comparison 2. Temozolomide versus radiotherapy in the elderly
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival (temozolomide alone
versus hypofractionated
radiotherapy) alone
1 242 Hazard Ratio (Random, 95% CI) 0.82 [0.63, 1.07]
2 Survival (temozolomide alone
versus standard radiotherapy
alone)
2 566 Hazard Ratio (Random, 95% CI) 0.88 [0.57, 1.36]
3 Progression free survival
(temozolomide alone versus
standard radiotherapy alone)
1 373 Hazard Ratio (Random, 95% CI) 1.15 [0.92, 1.44]
4 Adverse Events 2 5497 Odds Ratio (M-H, Random, 95% CI) 3.18 [1.81, 5.58]
4.1 Neutropaenia 2 653 Odds Ratio (M-H, Random, 95% CI) 52.21 [14.62, 186.
51]
4.2 Pancytopaenia 1 180 Odds Ratio (M-H, Random, 95% CI) 5.11 [0.24, 108.01]
4.3 Thrombocytopaenia 2 653 Odds Ratio (M-H, Random, 95% CI) 19.06 [1.14, 317.61]
4.4 Lymphocytpaenia 1 373 Odds Ratio (M-H, Random, 95% CI) 41.21 [16.22, 104.
73]
4.5 Thromboembolic event 2 653 Odds Ratio (M-H, Random, 95% CI) 2.12 [1.25, 3.58]
4.6 Infection 2 653 Odds Ratio (M-H, Random, 95% CI) 1.64 [1.14, 2.34]
4.7 Fatigue 2 653 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.67, 2.20]
4.8 Nausea/vomiting 2 653 Odds Ratio (M-H, Random, 95% CI) 4.03 [1.74, 9.32]
35Temozolomide for high grade glioma (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4.9 Seizures 2 653 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.51, 2.05]
4.10 Cutaneous 1 373 Odds Ratio (M-H, Random, 95% CI) 0.75 [0.37, 1.50]
Comparison 3. Different temozolomide dosing schedules
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 1 85 Hazard Ratio (Random, 95% CI) 0.84 [0.51, 1.40]
2 Adverse events 1 387 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.12 [1.15, 3.91]
2.1 Leucopaenia 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.59 [0.34, 19.40]
2.2 Neutropaenia 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.38 [0.22, 8.50]
2.3 Lymphopaenia 1 92 Peto Odds Ratio (Peto, Fixed, 95% CI) 5.09 [2.12, 12.18]
2.4 Thrombocytopaenia 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.45 [0.04, 4.52]
2.5 Elevation of
aminotransferases
1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 0.21 [0.04, 1.11]
2.6 Fatigue 1 59 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.59 [0.34, 19.40]
Comparison 4. Therapy for recurrent disease
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Survival 2 672 Hazard Ratio (Random, 95% CI) 0.90 [0.76, 1.06]
1.1 Grade 3 & 4 tumours 1 447 Hazard Ratio (Random, 95% CI) 0.91 [0.74, 1.12]
1.2 Grade 4 tumours only 1 225 Hazard Ratio (Random, 95% CI) 0.87 [0.65, 1.16]
2 Progression-Free Survival 2 672 Hazard Ratio (Random, 95% CI) 0.79 [0.61, 1.03]
2.1 Grade 3 & 4 tumours 1 447 Hazard Ratio (Random, 95% CI) 0.89 [0.73, 1.09]
2.2 Grade 4 tumours only 1 225 Hazard Ratio (Random, 95% CI) 0.68 [0.51, 0.90]
3 Adverse events 2 887 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.19 [0.81, 1.75]
3.1 All adverse events 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.53 [0.81, 2.89]
3.2 Haematological 1 447 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.01 [0.61, 1.65]
3.3 Fatigue 1 220 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.50 [0.26, 8.82]
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Analysis 1.1. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 1 Overall survival.
Review: Temozolomide for high grade glioma
Comparison: 1 Primary Concomitant/Adjuvant Therapy
Outcome: 1 Overall survival
Study or subgroup TMZ + RT RT only log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Concomitant and adjuvant therapy
EORTC/NCIC 26981-22981 287 286 -0.462 (0.0882) 49.5 % 0.63 [ 0.53, 0.75 ]
Athanassiou 2005 57 53 -0.7571 (0.1565) 34.7 % 0.47 [ 0.35, 0.64 ]
Subtotal (95% CI) 84.2 % 0.56 [ 0.42, 0.74 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.70, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 4.01 (P = 0.000060)
2 Concomitant therapy only
Kocher 2008 29 33 -0.1165 (0.3028) 15.8 % 0.89 [ 0.49, 1.61 ]
Subtotal (95% CI) 15.8 % 0.89 [ 0.49, 1.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
Total (95% CI) 100.0 % 0.60 [ 0.46, 0.79 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.48, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 3.66 (P = 0.00025)
Test for subgroup differences: Chi2 = 1.92, df = 1 (P = 0.17), I2 =48%
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Analysis 1.2. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 2 Progression-free survival.
Review: Temozolomide for high grade glioma
Comparison: 1 Primary Concomitant/Adjuvant Therapy
Outcome: 2 Progression-free survival
Study or subgroup TMZ+RT RT only log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Concomitant and adjuvant therapy
Athanassiou 2005 57 53 -0.7574 (0.2195) 29.9 % 0.47 [ 0.30, 0.72 ]
EORTC/NCIC 26981-22981 287 286 -0.588 (0.0884) 43.7 % 0.56 [ 0.47, 0.66 ]
Subtotal (95% CI) 73.6 % 0.54 [ 0.46, 0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 7.46 (P < 0.00001)
2 Concomitant therapy only
Kocher 2008 29 33 0.0619 (0.2553) 26.4 % 1.06 [ 0.65, 1.75 ]
Subtotal (95% CI) 26.4 % 1.06 [ 0.65, 1.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 100.0 % 0.63 [ 0.43, 0.92 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 6.82, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Chi2 = 6.31, df = 1 (P = 0.01), I2 =84%
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Analysis 1.3. Comparison 1 Primary Concomitant/Adjuvant Therapy, Outcome 3 Adverse events.
Review: Temozolomide for high grade glioma
Comparison: 1 Primary Concomitant/Adjuvant Therapy
Outcome: 3 Adverse events
Study or subgroup Temozolomide Control
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Total adverse events
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Temozolomide), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Haematological
EORTC/NCIC 26981-22981 46/287 0/286 27.0 % 8.73 [ 4.78, 15.94 ]
Kocher 2008 9/28 2/33 5.8 % 5.67 [ 1.55, 20.80 ]
Subtotal (95% CI) 315 319 32.8 % 8.09 [ 4.69, 13.97 ]
Total events: 55 (Temozolomide), 2 (Control)
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 7.50 (P < 0.00001)
3 Fatigue
EORTC/NCIC 26981-22981 38/287 20/286 33.2 % 1.98 [ 1.15, 3.41 ]
Subtotal (95% CI) 287 286 33.2 % 1.98 [ 1.15, 3.41 ]
Total events: 38 (Temozolomide), 20 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.48 (P = 0.013)
4 Thromboembolic
EORTC/NCIC 26981-22981 12/287 16/286 17.0 % 0.74 [ 0.35, 1.58 ]
Subtotal (95% CI) 287 286 17.0 % 0.74 [ 0.35, 1.58 ]
Total events: 12 (Temozolomide), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
5 Infections
EORTC/NCIC 26981-22981 20/287 8/286 17.0 % 2.45 [ 1.15, 5.23 ]
Subtotal (95% CI) 287 286 17.0 % 2.45 [ 1.15, 5.23 ]
Total events: 20 (Temozolomide), 8 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
Total (95% CI) 1176 1177 100.0 % 2.76 [ 2.02, 3.77 ]
Total events: 125 (Temozolomide), 46 (Control)
Heterogeneity: Chi2 = 28.35, df = 4 (P = 0.00001); I2 =86%
Test for overall effect: Z = 6.35 (P < 0.00001)
Test for subgroup differences: Chi2 = 28.00, df = 3 (P = 0.00), I2 =89%
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Analysis 2.1. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 1 Survival
(temozolomide alone versus hypofractionated radiotherapy) alone.
Review: Temozolomide for high grade glioma
Comparison: 2 Temozolomide versus radiotherapy in the elderly
Outcome: 1 Survival (temozolomide alone versus hypofractionated radiotherapy) alone
Study or subgroup Temozolomide Radiotherapy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Nordic 2012 119 123 -0.1985 (0.1345) 100.0 % 0.82 [ 0.63, 1.07 ]
Total (95% CI) 100.0 % 0.82 [ 0.63, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 2 Survival
(temozolomide alone versus standard radiotherapy alone).
Review: Temozolomide for high grade glioma
Comparison: 2 Temozolomide versus radiotherapy in the elderly
Outcome: 2 Survival (temozolomide alone versus standard radiotherapy alone)
Study or subgroup Temozolomide Radiotherapy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
NOA-08 2012 195 178 0.0862 (0.134) 51.3 % 1.09 [ 0.84, 1.42 ]
Nordic 2012 93 100 -0.3567 (0.1517) 48.7 % 0.70 [ 0.52, 0.94 ]
Total (95% CI) 100.0 % 0.88 [ 0.57, 1.36 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.79, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 0.59 (P = 0.56)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 3 Progression free
survival (temozolomide alone versus standard radiotherapy alone).
Review: Temozolomide for high grade glioma
Comparison: 2 Temozolomide versus radiotherapy in the elderly
Outcome: 3 Progression free survival (temozolomide alone versus standard radiotherapy alone)
Study or subgroup Temozolomide Radiotherapy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
NOA-08 2012 195 178 0.1398 (0.1138) 100.0 % 1.15 [ 0.92, 1.44 ]
Total (95% CI) 100.0 % 1.15 [ 0.92, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 Temozolomide versus radiotherapy in the elderly, Outcome 4 Adverse Events.
Review: Temozolomide for high grade glioma
Comparison: 2 Temozolomide versus radiotherapy in the elderly
Outcome: 4 Adverse Events
Study or subgroup Temozolomide alone Radiotherapy alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Neutropaenia
NOA-08 2012 72/195 2/178 5.2 % 51.51 [ 12.40, 213.92 ]
Nordic 2012 11/90 0/190 2.6 % 55.11 [ 3.21, 946.60 ]
Subtotal (95% CI) 285 368 7.8 % 52.21 [ 14.62, 186.51 ]
Total events: 83 (Temozolomide alone), 2 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 6.09 (P < 0.00001)
2 Pancytopaenia
Nordic 2012 2/90 0/90 2.4 % 5.11 [ 0.24, 108.01 ]
Subtotal (95% CI) 90 90 2.4 % 5.11 [ 0.24, 108.01 ]
Total events: 2 (Temozolomide alone), 0 (Radiotherapy alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 Thrombocytopaenia
NOA-08 2012 50/195 9/178 6.8 % 6.48 [ 3.08, 13.62 ]
Nordic 2012 19/90 0/190 2.6 % 103.91 [ 6.19, 1743.70 ]
Subtotal (95% CI) 285 368 9.5 % 19.06 [ 1.14, 317.61 ]
Total events: 69 (Temozolomide alone), 9 (Radiotherapy alone)
Heterogeneity: Tau2 = 3.23; Chi2 = 3.92, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 2.05 (P = 0.040)
4 Lymphocytpaenia
NOA-08 2012 106/195 5/178 6.4 % 41.21 [ 16.22, 104.73 ]
Subtotal (95% CI) 195 178 6.4 % 41.21 [ 16.22, 104.73 ]
Total events: 106 (Temozolomide alone), 5 (Radiotherapy alone)
Heterogeneity: not applicable
Test for overall effect: Z = 7.81 (P < 0.00001)
5 Thromboembolic event
NOA-08 2012 40/195 18/178 7.1 % 2.29 [ 1.26, 4.17 ]
Nordic 2012 6/90 8/190 6.0 % 1.63 [ 0.55, 4.83 ]
Subtotal (95% CI) 285 368 13.1 % 2.12 [ 1.25, 3.58 ]
Total events: 46 (Temozolomide alone), 26 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.30, df = 1 (P = 0.59); I2 =0.0%
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(. . . Continued)
Study or subgroup Temozolomide alone Radiotherapy alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.80 (P = 0.0051)
6 Infection
NOA-08 2012 89/195 63/178 7.4 % 1.53 [ 1.01, 2.33 ]
Nordic 2012 17/90 20/190 6.9 % 1.98 [ 0.98, 4.00 ]
Subtotal (95% CI) 285 368 14.4 % 1.64 [ 1.14, 2.34 ]
Total events: 106 (Temozolomide alone), 83 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
7 Fatigue
NOA-08 2012 61/195 43/178 7.4 % 1.43 [ 0.90, 2.26 ]
Nordic 2012 4/90 12/190 5.8 % 0.69 [ 0.22, 2.20 ]
Subtotal (95% CI) 285 368 13.2 % 1.22 [ 0.67, 2.20 ]
Total events: 65 (Temozolomide alone), 55 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.06; Chi2 = 1.31, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 0.65 (P = 0.52)
8 Nausea/vomiting
NOA-08 2012 38/195 7/178 6.6 % 5.91 [ 2.57, 13.62 ]
Nordic 2012 9/90 8/190 6.3 % 2.53 [ 0.94, 6.79 ]
Subtotal (95% CI) 285 368 12.9 % 4.03 [ 1.74, 9.32 ]
Total events: 47 (Temozolomide alone), 15 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.15; Chi2 = 1.70, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 3.26 (P = 0.0011)
9 Seizures
NOA-08 2012 31/195 22/178 7.1 % 1.34 [ 0.74, 2.41 ]
Nordic 2012 6/90 19/190 6.3 % 0.64 [ 0.25, 1.67 ]
Subtotal (95% CI) 285 368 13.5 % 1.03 [ 0.51, 2.05 ]
Total events: 37 (Temozolomide alone), 41 (Radiotherapy alone)
Heterogeneity: Tau2 = 0.11; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 0.07 (P = 0.94)
10 Cutaneous
NOA-08 2012 16/195 19/178 6.9 % 0.75 [ 0.37, 1.50 ]
Subtotal (95% CI) 195 178 6.9 % 0.75 [ 0.37, 1.50 ]
Total events: 16 (Temozolomide alone), 19 (Radiotherapy alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 2475 3022 100.0 % 3.18 [ 1.81, 5.58 ]
Total events: 577 (Temozolomide alone), 255 (Radiotherapy alone)
Heterogeneity: Tau2 = 1.07; Chi2 = 123.10, df = 16 (P<0.00001); I2 =87%
Test for overall effect: Z = 4.02 (P = 0.000058)
Test for subgroup differences: Chi2 = 86.19, df = 9 (P = 0.00), I2 =90%
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Analysis 3.1. Comparison 3 Different temozolomide dosing schedules, Outcome 1 Survival.
Review: Temozolomide for high grade glioma
Comparison: 3 Different temozolomide dosing schedules
Outcome: 1 Survival
Study or subgroup
Dose-dense
temozolo-
mide
Metronomic
temozolo-
mide log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Clarke 2009 42 43 -0.17 (0.26) 100.0 % 0.84 [ 0.51, 1.40 ]
Total (95% CI) 100.0 % 0.84 [ 0.51, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 Different temozolomide dosing schedules, Outcome 2 Adverse events.
Review: Temozolomide for high grade glioma
Comparison: 3 Different temozolomide dosing schedules
Outcome: 2 Adverse events
Study or subgroup
Dose-dense
temozolo-
mide
Metronomic
temozolo-
mide
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 Leucopaenia
Clarke 2009 3/31 1/28 9.3 % 2.59 [ 0.34, 19.40 ]
Subtotal (95% CI) 31 28 9.3 % 2.59 [ 0.34, 19.40 ]
Total events: 3 (Dose-dense temozolomide), 1 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
2 Neutropaenia
Clarke 2009 3/31 2/28 11.4 % 1.38 [ 0.22, 8.50 ]
Subtotal (95% CI) 31 28 11.4 % 1.38 [ 0.22, 8.50 ]
Total events: 3 (Dose-dense temozolomide), 2 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
3 Lymphopaenia
Clarke 2009 21/31 17/61 49.5 % 5.09 [ 2.12, 12.18 ]
Subtotal (95% CI) 31 61 49.5 % 5.09 [ 2.12, 12.18 ]
Total events: 21 (Dose-dense temozolomide), 17 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
4 Thrombocytopaenia
Clarke 2009 1/31 2/28 7.1 % 0.45 [ 0.04, 4.52 ]
Subtotal (95% CI) 31 28 7.1 % 0.45 [ 0.04, 4.52 ]
Total events: 1 (Dose-dense temozolomide), 2 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
5 Elevation of aminotransferases
Clarke 2009 1/31 5/28 13.4 % 0.21 [ 0.04, 1.11 ]
Subtotal (95% CI) 31 28 13.4 % 0.21 [ 0.04, 1.11 ]
Total events: 1 (Dose-dense temozolomide), 5 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
6 Fatigue
Clarke 2009 3/31 1/28 9.3 % 2.59 [ 0.34, 19.40 ]
Subtotal (95% CI) 31 28 9.3 % 2.59 [ 0.34, 19.40 ]
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(. . . Continued)
Study or subgroup
Dose-dense
temozolo-
mide
Metronomic
temozolo-
mide
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
Total events: 3 (Dose-dense temozolomide), 1 (Metronomic temozolomide)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Total (95% CI) 186 201 100.0 % 2.12 [ 1.15, 3.91 ]
Total events: 32 (Dose-dense temozolomide), 28 (Metronomic temozolomide)
Heterogeneity: Chi2 = 13.28, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Chi2 = 13.28, df = 5 (P = 0.02), I2 =62%
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Analysis 4.1. Comparison 4 Therapy for recurrent disease, Outcome 1 Survival.
Review: Temozolomide for high grade glioma
Comparison: 4 Therapy for recurrent disease
Outcome: 1 Survival
Study or subgroup Temozolomide
Nitrosourea
chemother-
apy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Grade 3 % 4 tumours
BR12 2010 224 223 -0.0943 (0.1055) 65.4 % 0.91 [ 0.74, 1.12 ]
Subtotal (95% CI) 65.4 % 0.91 [ 0.74, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
2 Grade 4 tumours only
Yung 2000a 112 113 -0.1397 (0.145) 34.6 % 0.87 [ 0.65, 1.16 ]
Subtotal (95% CI) 34.6 % 0.87 [ 0.65, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
Total (95% CI) 100.0 % 0.90 [ 0.76, 1.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Chi2 = 0.06, df = 1 (P = 0.80), I2 =0.0%
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Analysis 4.2. Comparison 4 Therapy for recurrent disease, Outcome 2 Progression-Free Survival.
Review: Temozolomide for high grade glioma
Comparison: 4 Therapy for recurrent disease
Outcome: 2 Progression-Free Survival
Study or subgroup Temozolomide
Nitrosourea
chemother-
apy log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Grade 3 % 4 tumours
BR12 2010 224 223 -0.1165 (0.102) 57.4 % 0.89 [ 0.73, 1.09 ]
Subtotal (95% CI) 57.4 % 0.89 [ 0.73, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
2 Grade 4 tumours only
Yung 2000a 112 113 -0.3852 (0.145) 42.6 % 0.68 [ 0.51, 0.90 ]
Subtotal (95% CI) 42.6 % 0.68 [ 0.51, 0.90 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0079)
Total (95% CI) 100.0 % 0.79 [ 0.61, 1.03 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.30, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.74 (P = 0.082)
Test for subgroup differences: Chi2 = 2.30, df = 1 (P = 0.13), I2 =56%
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Analysis 4.3. Comparison 4 Therapy for recurrent disease, Outcome 3 Adverse events.
Review: Temozolomide for high grade glioma
Comparison: 4 Therapy for recurrent disease
Outcome: 3 Adverse events
Study or subgroup Temozolomide
Nitrosourea
chemother-
apy
Peto
Odds Ratio Weight
Peto
Odds Ratio
n/N n/N Peto,Fixed,95% CI Peto,Fixed,95% CI
1 All adverse events
Yung 2000a 28/110 20/110 36.1 % 1.53 [ 0.81, 2.89 ]
Subtotal (95% CI) 110 110 36.1 % 1.53 [ 0.81, 2.89 ]
Total events: 28 (Temozolomide), 20 (Nitrosourea chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 1.30 (P = 0.19)
2 Haematological
BR12 2010 37/223 37/224 59.2 % 1.01 [ 0.61, 1.65 ]
Subtotal (95% CI) 223 224 59.2 % 1.01 [ 0.61, 1.65 ]
Total events: 37 (Temozolomide), 37 (Nitrosourea chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
3 Fatigue
Yung 2000a 3/110 2/110 4.7 % 1.50 [ 0.26, 8.82 ]
Subtotal (95% CI) 110 110 4.7 % 1.50 [ 0.26, 8.82 ]
Total events: 3 (Temozolomide), 2 (Nitrosourea chemotherapy)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
Total (95% CI) 443 444 100.0 % 1.19 [ 0.81, 1.75 ]
Total events: 68 (Temozolomide), 59 (Nitrosourea chemotherapy)
Heterogeneity: Chi2 = 1.10, df = 2 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Chi2 = 1.10, df = 2 (P = 0.58), I2 =0.0%
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A D D I T I O N A L T A B L E S
Table 1. Internal Validity
Measure Clarke 2009 EORTC/
NCIC
26981-
22981
Kocher
2008
Athanas-
siou
2005
Yung 2000a BR12 2010 Nordic
2012
NOA-08
2012
Power calcu-
lation?
Yes
(adequate
power)
Yes Yes No. Proba-
bly under
powered.
Yes. Ade-
quate power
(for PFS).
Yes Yes Yes
Proper ran-
domisation?
Not clear Yes Not stated Methods
not reported
Not clear Yes Yes Yes
Groups sim-
ilar at base-
line?
Probably
(no statisti-
cal test used)
Probably
(no statisti-
cal test used)
Proba-
bly not (but
no statistical
test used)
Yes No (greater
time to re-
lapse
and after ra-
diotherapy
in PCB)
Probably
(no statisti-
cal test used)
Yes Probably
(no statisti-
cal test used)
Investiga-
tors
blinded?
No No No No No No No No
Outcome
assessors
blinded?
No No No No No No No No
Patients
blinded?
No No No No No No No No
Eligi-
bility criteria
stated?
Yes Yes Yes Yes Yes Yes Yes Yes
Ob-
jective out-
come mea-
sures?
Yes Yes (except
progression)
Yes (except
progression)
Yes Yes (except
progression)
Yes Yes Yes
Analysis on
ITT basis?
Yes Yes (not
QoL)
Yes No Yes (not
QoL)
Yes No (only
291 or 342
enrolled pa-
tients anal-
ysed)
No (only
373 of 412
enrolled pa-
tients anal-
ysed)
All
patients ac-
counted for?
Yes Yes (not
QoL)
Yes Yes Yes (not
QoL)
Yes Yes (not
QOL)
Yes (not
QOL)
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Table 1. Internal Validity (Continued)
With-
drawals
specified?
Yes Yes (not
QoL)
Yes Yes Yes (not
QoL)
Yes Yes (not
QOL)
Yes (not
QOL)
With-
drawal rea-
sons given?
Yes Yes (not
QoL)
Yes Yes Yes (not
QoL)
Yes No Yes (not
QOL)
Inter-centre
consistency?
Single centre Not
reported
Not
reported
Not applica-
ble
Not
reported
Not
reported
Not
reported
Not
reported
Conflicts of
interest?
cCertain au-
thors had
a consultant
or
advisory role
with Scher-
ing-Plough
sSponsored
by Schering-
Plough
Ssponsored
by ESSEX
pharma®
None
declared
Certain
authors had
a consultant
or
advisory role
with Scher-
ing-Plough
Certain
authors had
a consultant
or
advisory role
with Scher-
ing-Plough
The trial was
sponsored
by Merck
but they had
no other role
in the study
The trial was
funded by
Merck
Sharp
and Dohme
but they had
no other role
in the study
PCB = procarbazine; PFS = progression-free survival; QoL = quality of life
Table 2. External Validity
Measure Clarke 2009 EORTC/
NCIC
26981-
22981
Kocher
2008
Athanas-
siou
2005
Yung 2000a BR12 2010 Nordic
2012
NOA-08
2012
Age (mean
and range)
Dose dense:
59.1 (30-
70)
Metro-
nomic:
54.1 (21-
71)
TMZ: 33%
< 50
RTx: 31% <
50
TMZ: 59
(34-67)
RTx: 58
(37-69)
TMZ:
42/53 > 50
RTx: 48/57
> 50
TMZ:
52 (21-76)
. PRO: 51
(21-74)
Median
age 53 both
arms
TMZ:
70 (60-88)
; HypoRTx:
70 (60-83);
RTx: 70
(60-80)
TMZ: 72
(68-44)
RTx: 71
(686-82)
Sex (M:F) Dose dense
29:13
Metro-
nomic
27:16
TMZ 64:36
RTx 61:39
TMZ 15:14
RTx 26:7
TMZ 64:36
RTx 61:39
TMZ 69:31
PCB 63:36
TMZ
63.7:36.3
PCV
65.2:34.8
TMZ: 59:
41
HypoRTx:
51:49
RTx: 68:32
TMZ: 45:
55
RTx: 49:51
Histology Local: GBM
100%
(no central
review)
Local: GBM
100%
Central
(85%):
Local: GBM
100%
(no central
Local: GBM
100%
(no central
Confirmed
GBM:
TMZ 91%
TMZ:
Grade 3 23.
3% Grade 4
Cen-
tral review in
87%:
TMZ:
GBM 91%,
AA 9%
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Table 2. External Validity (Continued)
GBM 93% review) review) PCB 96% 74.4%
PCV:
Grade 3 22.
8%
Grade 4 74.
1%
(All
confirmed
after central
review)
glioblas-
toma in
97% (no di-
agnosis - 3;
WHO II - 1;
WHO III -
4)
RTx:
GBM 86%,
AA 13%
(All
confirmed
after central
review)
Perfor-
mance Sta-
tus (mean
and range)
MedianKPS
90 all arms
TMZ: 39%
= 0, 47% =
1, 13% = 2
RTx: 38% =
0, 49% = 1,
12% = 0
TMZ:
WHO 2 = 0
RTx: WHO
2 = 2
TMZ: 47%
KPS
> 80 RTx:
32% KPS >
80.
KPS 70 or
more: TMZ
100% PCB
99%
TMZ: 0 =
20.2%, 1 =
43.5%, 2 =
24.7%
PCV:
0 = 15.2
1 = 48.2%
2 = 28.1%
TMZ:
WHO 0-1 =
78%,WHO
2-3 = 22%
HypoRTx:
WHO 0-1 =
80%,WHO
2-3 = 20%
RTx: WHO
0-1 = 72%,
WHO 2-3 =
28%
TMZ: KPS
80 (60-100)
RTx: 80
(60-100)
Extent of
Surgery
Dose dense:
biopsy 24%
total 43%
Metro-
nomic:
biopsy 21%
total 35%
TMZ: 17%
biopsy, 39%
complete
RTx: 16%
biopsy, 40%
complete
Macro-
scopic
complete tu-
mour resec-
tion: 100%
TMZ: total
=
18%, biopsy
= 42%.
RTxl: total =
15%, biopsy
= 42%
Previous re-
section:
TMZ 87%
PCB
91% Previ-
ous Chemo-
therapy:
TMZ 65%
PCB 68%
TMZ:
biopsy 26%
total 13.9%
PCV:
biopsy 26%
total 13.5%
TMZ:
biopsy 26%,
resection
74%
HypoRTx:
biopsy 27%,
resection
73%
RT: biopsy
27%, resec-
tion 73%
TMZ: com-
plete
27%, partial
31%, biopsy
41%, miss-
ing <1%
RTx: com-
plete 20%,
partial 35%,
biopsy 37%,
missing 0%
Follow-up Median 18.
8
months (un-
til 15 Dec
2008)
Median 61
months
(range 11
days to 79
months)
Not stated Median
11.2months
(range 3.4 to
27 months)
Not stated TMZ: 14
months
PCV: 10.5
months
Not stated
(but at study
close on 4
patients still
alive and 3
lost to fol-
low-up)
Minimum
follow-
up was 12
months
GBM = glioblastoma multiforme; PCB = procarbazine; PCV = procarbazine, lomustine and vincristine; RTx = radiotherapy; TMZ =
temozolomide
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Table 3. WHO Performance Status
Grade Definition
0 Fully active, able to carry on all pre-disease performance without restriction
1 Restricted in physically strenuous activity but ambulatory and ale to carry out work of a light or sedentary nature e.g. light
house work, office work
2 Ambulatory and capable of all self care, but unable to carry out ay work activities. Up and about more than 50% of waking
hours
3 Capable of only limited self care, confined to bed or chair more than 50% of waking hours
4 Completely disabled. Cannot carry out any self-care. Totally confined to bed or chair
5 Dead
Table 4. Karnofsky Performance Scale
Score Definition
100 Normal, no complaints, no evidence of disease
90 Able to carry on normal activity: minor symptoms of disease
80 Normal activity with effort: some symptoms of disease
70 Cares for self: unable to carry on normal activity or active work
60 Requires occasional assistance but is able to care for needs
50 Requires considerable assistance and frequent medical care
40 Disabled: requires special care and assistance
30 Severely disabled: hospitalisation is indicated, death not imminent
20 Very sick, hospitalisation necessary: active treatment necessary
10 Moribund, fatal processes progressing rapidly
0 Dead
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A P P E N D I C E S
Appendix 1. MEDLINE
The original search strategy has been adapted from the Ovid version to the Silver Platter version. Terms 1 to 37, used to identify all
randomized and clinical controlled trials were taken from the first two parts of the Highly Sensitive Search Strategy (HSSS) devised by
Carol Lefebvre.
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized controlled trials/
4. random allocation/
5. double-blind method/
6. single-blind method/
7. 1 or 2 or 3 or 4 or 5 or 6
8. limit 7 to animal
9. limit 7 to human
10. 8 and 9
11. 8 not 10
12. 7 not 11
13. clinical trial.pt.
14. exp clinical trials/
15. clin$ with trial$.tw.
16. placebos/
17. placebo$.tw.
18. random$.tw.
19. exp research design/
20. 13 or 14 or 15 or 16 or 17 or 18 or 19
21. limit 20 to animal
22. limit 20 to human
23. 21 and 22
24. 21 not 23
25. 20 not 24
26. comparitive study/
27. exp evaluation studies/
28. follow-up studies/
29. prospective studies/
30. (control$ or prospectiv$ or volunteer$).tw.
31. 26 or 27 or 28 or 29 or 30
32. limit 31 to animal
33. limit 31 to human
34. 32 and 33
35. 32 not 34
36. 31 not 35
37. 12 or 25 or 36
38. explode “Brain-Neoplasms”/ all subheadings
39. explode “Central-Nervous-System-Neoplasms”/ all subheadings
40. explode “Cerebral-Cortex”/ all subheadings
41. explode “Glioma”/ all subheadings
42. malignant near glioma*
43. glioblastoma* or “glioblastoma multiforme”
44. astrocytoma* or “anaplastic astrocytoma”
45. brain tumo?r*
46. neuroectodermal tumo?r*
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47. ependymoma*
48. oligodendroglioma*
49. or/38-48
50. temozolomide
51. temodar
52. temodal
53. or/50-52
54. 37 and 49 and 53
Appendix 2. EMBASE
The original search strategy has been adapted from Ovid version to SilverPlatter version, all “MESH” headings were checked in
Thesaurus (as the vocabulary was updated in January 2003) and minor changes were made in “MESH” terms.
1. explode “clinical-trial”/ all subheadings
2. explode “controlled-study”/ all subheadings
3. explode “meta-analysis”/ all subheadings
4. explode “crossover-procedure”/ all subheadings
5. explode “double-blind-procedure”/ all subheadings
6. explode “single-blind-procedure”/ all subheadings
7. explode “randomization”/ all subheadings
8. explode “prospective-study”/ all subheadings
9. clin* near trial*
10. singl*
11. double*
12. (singl* or double* or trebl* or tripl*) near (blind* or mask*)
13. random*
14. control*
15. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14
16. EC = “HUMAN”
17. #15 and (EC = “HUMAN”)
18. explode “brain-tumor”/ all subheadings
19. explode “central-nervous-system”/ all subheadings
20. explode “brain-cortex”/ all subheadings
21. malignant near glioma*
22. glioblastoma multiforme*
23. astrocytoma* or anaplastic astrocytoma*
24. brain tumo?r*
25. neuroectodermal tumo?r*
26. ependymoma*
27. oligodendroglioma*
28. #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27
29. temozolamide
30. temodar
31. temodal
32. #29 or #30 or #31
33. 15 and 28 and 32
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Appendix 3. SCIENCE CITATION INDEX (1981 to 2007)
A similar search strategy to the one for Biosis was used. Searches were made in the Title, Keyword or Abstract.
Unlike Biosis, there was no “major concepts” search facility.
The differences were as follows:
1. “tumo*” was used in place of “tumo*r”
2. “central & nervous & system & tumo*” and “central & nervous & system & neoplasm” were two additional searches.
Appendix 4. CENTRAL
Capital letters are MESH terms, the rest are free text terms. The original search strategy was used.
1. CENTRAL NERVOUS SYSTEM NEOPLASMS
2. BRAIN NEOPLASMS
3. GLIOMA
4. (malignant and glioma)
5. (glioblastoma and multiforme)
6. astrocytoma*
7. (anaplastic and astrocytoma*)
8. (brain and tumor*)
9. (neuroectodermal and tumor*)
10. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9)
11. Temozolamide
12. Temodar
13. Temodal
14. (#11 or #12 or #13)
15. #10 and #14
Appendix 5. Physician Data Query (PDQ)
http://www.nci.nih.gov/cancertopics/pdq
The search followed the prescribed searching forms specific for the database, using terms from the above searches.
Search form - all types of brain tumours - adults, children
Treatment
Active and closed
Phase III and IV
Temozolamide
Appendix 6. meta-Register of Controlled Trials (mRCT)
Keywords: brain, glioma, temozolamide
Appendix 7. CENTRAL search strategy update
#1 MeSH descriptor Glioma explode all trees
#2 glioma*
#3 astrocytoma*
#4 oligodendroglioma*
#5 oligoastrocytoma*
#6 glioblastoma*
#7 GBM
#8 ependymoma*
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#9 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
Appendix 8. MEDLINE search strategy update
1 exp Glioma/
2 glioma*.mp.
3 astrocytoma*.mp.
4 oligodendroglioma*.mp.
5 oligoastrocytoma*.mp.
6 glioblastoma*.mp.
7 GBM.mp.
8 ependymoma*.mp.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 randomized controlled trial.pt.
11 controlled clinical trial.pt.
12 randomized.ab.
13 placebo.ab.
14 clinical trials as topic.sh.
15 randomly.ab.
16 trial.ti.
17 10 or 11 or 12 or 13 or 14 or 15 or 16
18 9 and 17
Appendix 9. EMBASE search strategy update
1 exp glioma/
2 glioma*.mp.
3 astrocytoma*.mp.
4 oligodendroglioma*.mp.
5 oligoastrocytoma*.mp.
6 glioblastoma*.mp.
7 GBM.mp.
8 ependymoma*.mp.
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 crossover procedure/
11 double blind procedure/
12 randomized controlled trial/
13 single blind procedure/
14 random*.mp.
15 factorial*.mp.
16 crossover*.mp.
17 cross over*.mp.
18 cross-over*.mp.
19 placebo*.mp.
20 (doubl* adj blind*).mp.
21 (singl* adj blind*).mp.
22 assign*.mp.
23 allocat*.mp.
24 volunteer*.mp.
25 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
26 9 and 25
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WH A T ’ S N E W
Last assessed as up-to-date: 6 March 2013.
Date Event Description
6 March 2013 New citation required but conclusions have not
changed
Review updated; text substantially re-written and new
studies added but conclusions not changed
12 December 2012 New search has been performed Search strategy dates amended
H I S T O R Y
Review first published: Issue 4, 2008
Date Event Description
3 November 2009 Amended Minor amendment made in results section due to an error in transcribing the data from the figures
Temozolomide resulted in an increase in survival (HR 0.84, 95% CI 0.50 to 0.68, P < 0.001)
compared with the control arm now reads Temozolomide resulted in an increase in survival (HR
0.58, 95% CI 0.50 to 0.68, P < 0.001) compared with the control arm
C O N T R I B U T I O N S O F A U T H O R S
Michael Hart led and wrote the original review. Ruth Garside assisted with the screening, data checking and ran the paired study and
was aided by Gabriel Rogers, Margaret Somerville and Ken Stein in the original review. Robin Grant supervised the review and was
involved with the final editing process. Michael Hart updated the review in 2013.
D E C L A R A T I O N S O F I N T E R E S T
All authors report no conflict of interest.
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S O U R C E S O F S U P P O R T
Internal sources
• Dr Michael Hart was a recipient of a Cochrane Review Grant, UK.
External sources
• No sources of support supplied
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antineoplastic Agents, Alkylating [∗therapeutic use]; BrainNeoplasms [∗drug therapy];Dacarbazine [∗analogs&derivatives; therapeutic
use]; Glioblastoma [∗drug therapy]; Neoplasm Recurrence, Local [drug therapy]
MeSH check words
Humans
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